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Abstract
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed
in children, representing nearly one-third of all pediatric cancers. Although
current treatment protocols can cure approximately 80% of pediatric ALL
patients, a number of children will relapse, with a relapse rate shown to vary
within a group of patients with similar risk even though their leukemia blast
carry the same characteristics. Indeed, genetic variations involved in drug
metabolism could, at least partially, be responsible for heterogeneous responses
to standardized leukemia treatments, hence requiring more personalized therapy.
Pharmacogenetics investigates genetic variations that affect pharmacokinetics
and pharmacodynamics of drugs by changing the structure of proteins involved
in drug metabolism and cellular transport, and their influence on drug response
phenotypes. The methotrexate (MTX) and 6-mercaptopurine (6-MP) are an
essential part of the multi-drug regimens used for successful treatment of chi...
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Predictors of Treatment Toxicity and Prognosis 
in Pediatric Acute Lymphoblastic Leukemia 
in Belgian and Vietnamese Populations 
 
Summary 
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children, 
representing nearly one-third of all pediatric cancers. Although current treatment protocols 
can cure approximately 80% of pediatric ALL patients, a number of children will relapse, 
with a relapse rate shown to vary within a group of patients with similar risk even though 
their leukemia blast carry the same characteristics. Indeed, genetic variations involved in drug 
metabolism could, at least partially, be responsible for heterogeneous responses to 
standardized leukemia treatments, hence requiring more personalized therapy. 
Pharmacogenetics investigates genetic variations that affect pharmacokinetics and 
pharmacodynamics of drugs by changing the structure of proteins involved in drug 
metabolism and cellular transport, and their influence on drug response phenotypes. 
The methotrexate (MTX) and 6-mercaptopurine (6-MP) are an essential part of the multi-
drug regimens used for successful treatment of childhood ALL. Although MTX and 
thiopurines have been in use for over sixty years, there is significant uncertainty associated 
with their use, which is mainly caused by inter-individual differences in the bioavailability 
and metabolism of these extensively metabolized drugs. 
Study I:  
We compared the relapse free survival (RFS) in Vietnamese (n=141) and Caucasian (n=94) 
children with ALL living in Vietnam and Belgium, respectively, and treated by the same 
FRALLE 2000 protocol. 
RFS was significantly worse in Vietnamese children (hazards ratio=4.48; 95% confidence 
interval [CI], 2.16-9.3; P<0.01). The 5-year RFS was 83.8% (95% CI, 76.3%-92.0%) and 
47.8% (95% CI, 35.6%-64.2%) for Caucasian and Vietnamese children, respectively. In 
Vietnamese group, relapses occurred in bone marrow (BM) and cerebrospinal fluid (CSF) at 
a much earlier stage. 
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Several factors may contribute to the poor RFS in Vietnamese children, which include the 
time interval before the first intrathecal therapy and differences in the management of 
drugrelated toxicity. However, additional contribution of socioeconomic factors and/or 
variations in pharmacogenetic polymorphisms in Vietnamese patients cannot currently be 
ruled out. 
Study II: 
The aims of this study were to (a) to determine the prevalence of seven common genetic 
polymorphisms (cyclin D1 (CCND1) G870A, ɣ-glutamyl hydrolase (GGH) C452T, inosine 
triphosphatase (ITPA) C94A, methylenetetrahydrofolate reductase (MTHFR) A1298C, 
MTHFR C677T, thymidylate synthase (TSER), and thiopurine methyltransferase (TPMT)) 
including those that affect the folate and thiopurine metabolic pathways between two clinical 
series and (b) to assess the impact of seven genetic polymorphisms on RFS between 
Vietnamese clinical series (n= 141) and Caucasian (n=94) clinical series. 
The prevalence of MTHFR-677TT genotype was significantly higher in Caucasians 
(P=0.008), in contrast to the prevalence of TYMS-TSER*3R/3R and ITPA-94AA/AC 
genotypes which were significantly higher in Vietnamese (P<0.001 and P=0.02, 
respectively). Compared with children with a low MGRS (≤3), those with a high MGRS (≥4) 
were 2.06 (95% CI = 1.01, 4.22; P = 0.04) times more likely to relapse. Adding MGRS into a 
multivariate Cox regression model with race/ethnicity and four clinical variables improved 
the predictive accuracy of the model (AUC from 0.682 to 0.709 at 24 months). 
Including multilocus genetic risk score (MGRS) into a clinical model improved the predictive 
accuracy of short and medium term prognosis, hence confirming the association between well 
determined pharmacogenotypes and outcome of paediatric ALL. Whether variants on other 
genes associated with folate metabolism can substantially improve the predictive value of 
current MGRS is not known but deserves further evaluation. 
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Résumé 
La leucémie lymphoblastique aiguë (LLA) est le cancer le plus fréquent chez l’enfant et 
représente environ un tiers d’entre eux. Même si de nos jours, les protocoles de traitement 
parviennent à guérir près de 80% des enfants atteints de LLA, un certain nombre d’enfants 
rechutera, avec un taux de rechute qui varie, alors que nous sommes en présence d’un groupe 
de patients homogène au niveau des facteurs de risque et avec des caractéristiques identiques 
au niveau des blastes leucémiques. Des variations au niveau des gènes impliqués dans le 
métabolisme des médicaments pourraient en partie être responsables de cette hétérogénéité de 
réponse à un traitement standard, nous encourageant à évoluer vers des traitements plus 
personnalisés. La pharmacogénétique étudie les variations génétiques qui influencent la 
pharmacocinétique et la pharmacodynamique des drogues, en modifiant la structure des 
protéines impliquées dans le métabolisme médicamenteux et leur transport cellulaire ainsi 
que leur influence sur la réponse thérapeutique. 
Le MTX et 6-MP sont essentiels dans les conditionnements impliquant des multiples 
chimiothérapies, nécessaires pour l’obtention de succès thérapeutiques dans la LLA. Même si 
le MTX et les thiopurines ont été utilisés depuis plus de soixante ans, il existe une certaine 
incertitude liée à leur utilisation, essentiellement due aux différences entre individus au 
niveau de la biodisponibilité et du métabolisme de ces drogues. 
Premier article : 
Dans notre première étude, nous avons comparé la survie sans rechute d’enfants Vietnamiens 
(n=141) et d’enfants Caucasiens (n=94) atteints de LLA, vivant au Vietnam et en Belgique et 
traités selon le même protocole FRALLE 2000.  
La survie sans rechute était significativement plus mauvaise chez les enfants Vietnamiens 
(hazards ratio=4.48; 95% confidence interval [CI], 2.16-9.3; P<0.01). La survie sans rechute 
à 5 ans est de 83.8% (95% CI, 76.3%-92.0%) et 47.8% (95% CI, 35.6%-64.2%) pour les 
enfants de race blanche et Vietnamiens respectivement. Dans le groupe d’enfants 
Vietnamiens, la rechute au niveau médullaire et du système nerveux centrale survient de 
façon plus précoce.  
Plusieurs facteurs peuvent intervenir dont le temps écoulé entre le diagnostic et la première 
injection intrathécale ainsi que des différences d’adaptation de traitement au niveau de la 
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toxicité médicamenteuse. De plus des facteurs socio-économiques et/ou des différences de 
polymorphismes pharmacogénétiques ne peuvent être exclus et ont mené à l’étude suivante. 
Deuxième article : 
La deuxième étude vise (a) à analyser la prévalence de sept polymorphismes génétiques 
(CCND1 G870A, GGH C452T, ITPA C94A, MTHFR A1298C, MTHFR C677T, TSER, and 
TPMT) y compris ceux qui influencent le métabolisme des folates et thiopurines entre les 
deux groupes et (b) à évaluer l’impact de ces polymorphismes sur la survie sans rechute des 
enfants Vietnamiens et Caucasiens.  
La prévalence du génotype MTHFR-677TT était significativement plus élevée chez les 
Caucasiens (P= 0.008) par rapport aux génotypes TYMS-TSER*3R/3R et ITPA-94AA/AC qui 
étaient significativement plus fréquents chez les Vietnamiens (P<0.001 et P=0.02). Comparés 
aux enfants avec un MGRS bas (≤3), ceux qui ont un MGRS élevé (≥4) ont 2.06 fois plus de 
risque de rechute (95% CI = 1.01, 4.22; P = 0.04).  
Le fait d’ajouter MGRS dans un modèle de régression multivariée de Cox au facteur 
race/groupe ethnique et à quatre variables cliniques augmente la précision du modèle (AUC 
de 0.682 à 0.709 au 24 mois) au niveau du pronostic à court et moyen terme, confirmant 
l’association entre certains pharmacogénotypes et le pronostic de la LLA chez l’enfant. Reste 
à déterminer si l’adjonction de l’analyse d’autres gènes associés au métabolisme des folates 
peut encore améliorer la valeur prédictive des MGRS telle que présentée ici.  
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1. Introduction 
Acute lymphoblastic leukemia 
ALL is a fast-growing cancer of a type of white blood cells (WBC) called lymphocytes. 
These cells are found in the BM and other parts of the body. ALL occurs when the body 
produces a large number of immature lymphocytes. The cancer cells grow quickly and 
replace normal cells in the BM. BM is the soft tissue in the centre of bones that helps form all 
blood cells. Leukemic cells accumulate in the BM, replace normal blood cells and spread to 
other organs including liver, spleen, lymph nodes, central nervous system (CNS), kidneys and 
gonads. ALL prevents healthy blood cells from being made. Life-threatening symptoms can 
occur. 
Cause, incidence and risk factors 
Most of the time, no clear cause can be found for ALL. But the following may play a role in 
the development of leukemia in general: 
- Chromosomal abnormalities 
- Exposure to radiation, including x-rays before birth 
- Past treatment with chemotherapy drugs 
- Receiving a BM transplant 
- Toxins such as benzene 
The following increase the risk of ALL: 
- Down syndrome or other genetic disorders 
- A brother or sister with leukemia 
This type of leukemia usually affects children aged 3 to 7. ALL is the most common 
childhood cancer, but it can also occur in adults. 
Acute leukemias represent a clonal expansion and arrest at a specific stage of normal myeloid 
or lymphoid hematopoiesis (Hoffbrand and Mehta 2005). The leukemogenic event may occur 
in committed lymphoid cells of B- or T-cell lineages or in early precursors, which gives rise 
to the different subtypes of ALL based on the stage of lymphoid differentiation of the cell in 
which the event occurred (Reaman 2002). About 80% of all cases of ALL express cell-
surface markers indicative of a precursor B-cell lineage. Only 1% to 2% of cases express a 
phenotype typical of a mature B cell. T-cell ALL accounts for about 15% to 20% of cases and 
is commonly associated with features at diagnosis, such as older age, male predominance, 
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high WBC and extramedullary (EM) disease, all of which indicate the need for increased 
intensity of chemotherapy (Pizzo, Poplack et al. 2006). 
 
Figure 1: Blood cell development.  A blood stem cell goes through several steps to become a red 
blood cell, platelet, or white blood cell (National Cancer Institute USA., 2010). 
Bone marrow is found in the center of most bones and has many blood vessels. There are two 
types of bone marrow: red and yellow. Red marrow contains blood stem cells that can 
become red blood cells, white blood cells, or platelets. Yellow marrow is made mostly of fat. 
A myeloid stem cell becomes one of three types of mature blood cells: red blood cells, white 
blood cells and platelets. A lymphoid stem cell becomes a lymphoblast cell and then one of 
three types of lymphocytes (white blood cells): B lymphocytes, T lymphocytes and natural 
killers cells. 
Cure rates of B-cell–progenitor ALL among children are very high, but they are not as high 
among adults. Approximately one fifth of children with B-cell progenitor ALL have recurring 
disease, which is difficult to treat. Thus, this form of ALL varies with respect to the potential 
for relapse and resistance to chemotherapy. It is generally accepted that B-cell–progenitor 
ALL originates in B-cell restricted progenitors that have accumulated critical genetic lesions. 
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Cytogenetic studies of B-cell–progenitor ALL have revealed aberrations in chromosomal 
sites of regulatory molecules that are implicated in signaling and transcriptional regulation 
(Greaves and Wiemels 2003). 
Multiple genetic hits to deoxyribbonucleic acid (DNA) are necessary to cause cancer and 
when cancer strikes in childhood it is probably due to only a few severe genetic hits. Thus in 
childhood ALL we see the same genetic alterations in more than half of the children 
(hyperdiploidy 35% and t(12;21) translocation 25%). However these alterations alone are not 
enough to cause cancer; 0.5% of adults harbour the t(12;21) translocation and have never had 
childhood ALL (Olsen, Madsen et al. 2006). 
We do not know the cause of the initiating genetic alteration. Suggestions include chemicals, 
ionising radiation, food, smoking, past chemotherapy, and delayed infection. The hypothesis 
of delayed infections is based on the theory that early exposures to common infectious agents 
are required for the proper maturation of the immune system, lack of these exposures results 
in aberrant responses when children are finally in contact with the agent. ALL develops in the 
biological context of an aberrant immune response due to delayed infections, and thus, the 
infectious agents are only an indirect trigger of the leukemogenic process. The latter 
hypothesis (Hayashi, Fujimaki et al. 2007) is supported by a study showing that children in 
day-care have reduced risk of childhood cancer compared to children with less contact to 
other and thus less exposure to infections (Urayama, Buffler et al. 2010). In the industrialized 
parts of the world, we see more cases of childhood ALL; this could also support Greaves’s 
hypotheses as children in the Western world have fewer infections due, for example, to 
vaccinations programs. 
ALL in children is a rare disease, but devastating when it occurs. It offers a unique treatment 
challenge to the pediatrician. Not long ago this diagnosis was tantamount to a death sentence, 
but today the disease is curable in the majority of patients treated with effective 
chemotherapy, in combination with intensive supportive care. As survival has improved, it 
has become increasingly possible to define both inherent and treatment-related adverse 
prognostic features. The treatment has advanced from use of single agents to combination 
therapy, and today it is complex and multidisciplinary. 
The prognosis has improved considerably in the last two decades (Schrappe, Camitta et al. 
2000). In the Nordic countries the overall event-free survival has risen from 57 to 75%. 
Children without unfavourable features have benefited most strikingly from the 
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intensification of therapy (event-free survival is today 80-85%). As they constitute almost 
70% of all patients, the improvement has made a great impact on the overall result. However, 
in children with high-risk ALL, the progress has only been modest. The relapse rate has of 
course decreased in parallel with the improving results, but the prognosis after relapse has not 
improved during the above mentioned period. Only about 25-30% of children who relapse 
will reach and remain in a second remission. Cytotoxic treatment in FRALLE 2000 protocol 
for childhood ALL is divided into four essential phases: induction, consolidation, 
intensification and maintenance phase.  
Both molecular and immunological criteria are widely used in contemporary treatment 
protocols. 
The FRALLE 2000 criteria for standard and high-risk ALL form a good basis for comparing 
the treatment results of different protocols, but they are not sufficiently specific for modern 
stratification of treatment. Stratification of treatment aims at finding those children who need 
intensive treatment, but on the other hand, also those whose treatment could be less intensive 
and thus lead to less adverse effects.  
So, general aims of the study were to find new possible predictive factors in childhood ALL, 
and in the context of contemporary intensive treatment, to assess the value of established 
predictive factors for adverse effects of MTX and 6-MP in treatment. 
Epidemiology 
Until the 1940’s there were no effective treatments for leukemia in children. However after 
recognising that folic acid seemed to accelerate the disease, Sidney Farber introduced the 
folate antagonist, aminopterin, into the treatment in 1948 and was the first to induce 
remission in children with ALL (Miller 2006). Today we individualize treatment in childhood 
leukemia based on pharmacology, cytomorphology, immunology, cytogenetics and molecular 
biology (minimal residual disease (MRD)) (Whitehead, Vuchich et al. 1992, Barredo, Synold 
et al. 1994, Synold, Relling et al. 1994, Evans, Relling et al. 1998, Coustan-Smith, Sancho et 
al. 2000) and pharmacogenetics as mentioned earlier with the example with TPMT and 6-
MP. 
ALL is the most common cancer in children, accounting for 75-80% of all acute leukemias in 
children. Approximately half to two-third of ALL cases occur in children. An incident peak is 
seen between 2 and 5 years among children living in the Western world (Greaves 2006). 
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Every year approximately 180-200 children are diagnosed with ALL in the Nordic countries 
(Denmark, Finland, Iceland, Norway and Sweden) (Gustafsson, Schmiegelow et al. 2000); 
and 110-125 children are diagnosed with ALL in Pakistan (2000-2004) (Yasmeen and Ashraf 
2009). 
Compared to the total cancer burden in Belgium, childhood cancer comprises less than 1%. 
Every year, about 320 children (0-14 years) and 175 adolescents (15-19 years) are diagnosed 
with cancer (Belgian-Cancer-Registry 2010). Between 2004 and 2009 a total number of 625 
new diagnoses of leukemia are registered in children (N = 500) and adolescents (N = 125) in 
Belgium. The most frequent subtype, acute lymphoid leukaemia, represents 74% of the total 
number of leukaemia cases. In this age group (1-9 years) ALL represents 80% or more of all 
leukaemia diagnoses. From the age of 10 years onwards, the incidence rates for ALL remain 
fairly stable (Belgian-Cancer-Registry 2010). 
Until recently, there has been very little information on the pattern of occurrence of 
childhood cancer in Vietnam. Incidence rates of childhood cancer for the Cancer Centre 
Hospital at Ho Chi Minh city are presented for the first time for 3 years period 1995-1997 in 
Paediatric and Perinatal Epidemiology 2000. A total of 302 cancer cases were registered in 
children under 15 years of age, with a male to female ratio of 1:1. Leukaemia (principally 
ALL), brain tumours and lymphomas were the most common childhood neoplasms. Among 
121 cases of leukemia, ALL was the most common subcategory, accounting for 66%. It 
occurred most commonly 41% in the age 3-5 rears group. In 1995, the incidence of ALL 
observed in Cancer Centre Hospital at Ho Chi Minh city and elsewhere in south-east Asia is 
lower than in the white Caucasian population of Australia, Europe and North America (Quoc, 
Hung et al. 2000). 
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FRALLE 2000 protocol 
FRALLE 2000 protocol is shown in Figure 2. Drugs used in treatment FRALLE 2000 
protocol are shown in Table 1. Patients were assigned on sub-groups A1/A2/A3, B1/B2 or 
T1/T2 according to the results of flow cytometry, myelogram on day 21 and/or MRD 
evaluated at day 35. 
 
 
Figure 2: Diagram of Phases in FRALLE 2000 protocol. 
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Table 1: Treatment with FRALLE 2000 protocol details 
Phase/Drugs Daily Dose Days of Application per Element Note of toxicity/dose 
Pre-phase 
- Prednisone  (oral or IV) 
- MTX  (IT) 
 
60mg/m
2
/d 
8-15 mg 
 
 
D1 – D7 continuous 
D1  
 
 
 
Induction 
- Dexamethasone  (oral or IV) 
- Prednisone  (oral or IV) 
- Vincristine  (IV) * 
- Daunorubicine    (IVC in 1h) 
 
- L-Asparaginase   (IVC in 1h) 
 
- Endoxan   (IVC in 1h) 
- MTX  (IT) 
- Aracytine  (IT) 
- Depomedrol  (IT) 
 
  6mg/m
2
/d 
40mg/m
2
/d 
1,5mg/m
2
/injection (2mg max) 
40mg/m
2
/injection 
 
6.000 UI/m
2
/injection 
 
1.000mg/m
2
/injection 
8-15 mg 
15-30 mg 
20 mg 
 
 
D8 – D28 continuous, reduce dose - off D35 
D8 – D28 continuous, reduce dose - off D35 
D8-15-22-29 
D22-29 or D8-15-22-23(+/-)-29 
D8-9-10-15 
D10-12-14-16-18-20-22-24-26 
D8-10-12-15-17-19-22-24-26 
D22 or D8 
D8-15 
D8-15 
D8-15 
 
Group A 
Group B/T 
 
Group A3 or B 
Group T 
Group A/B 
Group T 
Group B2 or T 
Single in A 
Triple in B/T 
Triple in B/T 
Consolidation 
Cycle 1 
- Lanvis   (oral) 
- Vepeside   (IVC in 1h) 
- Aracytine  (SC) 
- Endoxan  (IVC in 1h) 
- MTX  (IT) 
- Aracytine  (IT) 
- Depomedrol  (IT) 
Cycle 2 
- Dexamethasone  (oral or IV) 
- Prednisone  (oral or IV) 
- Mercaptopurine   (oral) 
 
- Vincristine  (IV) * 
- MTX-HD  (IVC in 24h) 
- MTX  (oral) 
 
 
60mg/m
2
/d 
150mg/m
2
/injection 
30mg/m
2
/injection 
1.000mg/m
2
/injection 
8-15 mg 
15-30 mg 
20 mg 
 
  6mg/m
2
/d 
40mg/m
2
/d 
75mg/m
2
/d 
50mg/m
2
/d 
1,5mg/m
2
/injection 
5.000mg/m
2
/d 
25mg/m
2
/ 
 
 
D1 – D21 continuous 
D1-8-15 
D1-2/ D8-9/ D15-16 
D1-15 
D1- 30 
D1- 30 
D1- 30 
 
D1-D5/ D29-D33/D57-D61 continuous 
D29 - D35 continuous 
D1 - D77 continuous 
D29 - D35 continuous 
D1-8-29-36-57-64  or  D29-43 
D29- 43 
D36  or  D8-15-22-36-43-50-64-71-78 
 
B1 or T1 
B1/T1 
B1 
B1/T1 
T1 
B1 
B1 
B1 
A1/A2/B1/T1 
A1/A2 
B1/T1 
A1/A2 
B1/T1 
A1/A2 or  B1/T1 
B1/T1 (higher toxicity) 
B1/T1  or  A1/A2 
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Phase/Drugs Daily Dose Days of Application per Element Note of toxicity/dose 
- MTX  (IT) 
 
- Aracytine  (IT) 
- Depomedrol  (IT) 
 
Or  VEDA1/COPADM/VEDA2 
VEDA 
- Dexamethasone  (oral or IV) 
- Vincristine  (IV) * 
- Aracytine  (IVL in 1h) ** 
- Vepeside   (IVL in 1h) 
- MTX  (IT) 
- Aracytine  (IT) 
- Depomedrol  (IT) 
COPADM 
- Prednisone  (oral or IV) 
- Vincristine  (IV) * 
- Adriamycine   (IVL in 1h) 
- Endoxan    (IVC in 1h) 
- MTX-HD  (IVC in 24h) 
- MTX  (IT) 
- Aracytine  (IT) 
- Depomedrol  (IT) 
8-15 mg 
8-15 mg 
15-30 mg 
20 mg 
 
 
 
20mg/m
2
/d 
1,5mg/m
2
/injection 
2.000mg/m
2
/injection (8g max) 
150mg/m
2
/d 
8-15 mg 
15-30 mg 
20 mg 
 
60mg/m
2
/d 
1,5mg/m
2
/injection 
40mg/m
2
/d 
1.000mg/m
2
/injection 
5.000mg/m
2
/d 
8-15 mg 
15-30 mg 
20 mg 
D2-30-58 
D1-30-44  or  D1-15-30-44 
D1-30-44  or  D1-15-30-44 
D1-30-44  or  D1-15-30-44 
 
 
 
D1-D5 continuous 
D1 
D1-2 
D3-4-5 
D5 
D5 
D5 
 
D1 – D5 continuous 
D1 
D2 
D2-3 
D1 
D2 
D2 
D2 
Single in A1/A2 
B1 or  T1 
B1 or  T1 
B1 or  T1 
 
 
A3 or  B2 
 
 
 
 
Single in A3 
Triple in B2 
Triple in B2 
 
 
 
 
 
Higher toxicity 
Single in A3 
Triple in B2 
Triple in B2 
Intensification I 
Cycle 1 
- Dexamethasone  (oral or IV)*** 
- Vindesine  (IV)  **** 
- Adramycine  (IVC in 1h) 
- L-Asparaginase   (IVC in 1h) 
Cycle 2 
- Lanvis  (oral or IV) 
- Vepeside  (IVC in 1h) 
- Aracytine  (SC) 
- MTX  (IT) 
 
- Aracytine  (IT) 
- Depomedrol  (IT) 
 
 
10mg/m
2
/d  (10mg max) 
3mg/m
2
/injection  (4mg max) 
25mg/m
2
/injection 
6.000mg/m
2
/injection 
 
60mg/m
2
/d 
150mg/m
2
/injection 
30mg/m
2
/injection 
8-15 mg 
8-15 mg 
15-30 mg 
20 mg 
 
 
D1 – D14 continuous, reduce dose - off D21 
D1-8-15 
D1-8-15 
D4-6-8-10-12-15 
 
D29 – D49 continuous 
D29-36-43 
D29-30/ D36-37/ D43-44 
D3-30 
D1-29 
D1-29 
D1-29 
 
 
 
 
 
 
 
 
 
 
Single A 
Triple B/T 
Triple B/T 
Triple B/T 
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Phase/Drugs Daily Dose Days of Application per Element Note of toxicity/dose 
Interphase 
- Dexamethasone  (oral or IV) 
- Prednisone  (oral or IV) 
- Mercaptopurine   (oral) 
 
- Vincristine (IV) * 
- MTX-HD    (IVC in 24h) 
 
- MTX   (oral) 
 
- MTX  (IT) 
 
- Aracytine  (IT) 
- Depomedrol  (IT) 
 
6mg/m
2
/d 
40mg/m
2
/d 
50mg/m
2
/d 
75mg/m
2
/d 
1,5mg/m
2
/injection 
5.000mg/m
2
/d 
 
25mg/m
2
/d 
 
8-15 mg 
8-15 mg 
15-30 mg 
20 mg 
 
 
D1-D5/ D29-D33 continuous 
D1-D5/ D29-D35 continuous 
D1 – D49 continuous 
D1 – D49 continuous 
D15  or  D1-15-29-43(+/-) 
D1-29 
D1-15-29-43(+/-) 
D8-15-22-36-43-50   
D8-22-36  or  D8-22-36-43-50 
D2-16-30  or  D2-30 
D2-30  or  D2-16-30-44 
D2-30  or  D2-16-30-44 
D2-30  or  D2-16-30-44 
 
A 
B/T 
A3/B/T 
A1/A2 
A3  or  B/T 
B1 
A3/B2/T 
A1/A2 
B/T  or A3 
Single A3 or A1/A2 
B  or  T 
B  or  T 
B  or  T 
Intensification II 
Cycle 1 
- Prednisone  (oral or IV) 
- Vincristine  (IV) * 
 
- Daunorubicine   (IVC in 1h) 
- L-Asparaginase  (IVC in 1h) 
 
- MTX- DI  (IVC) 
- MTX  (IT) 
 
- Aracytine  (IT) 
- Depomedrol  (IT) 
Cycle 2 
- Lanvis   (oral or IV) 
- Endoxan  (IVC in 1h) 
- Aracytine  (SC) 
 
 
40mg/m
2
/d 
1,5mg/m
2
/injection (2mg max) 
 
40mg/m
2
/injection 
20.000mg/m
2
/injection 
6.000mg/m
2
/injection 
100mg/m
2
/injection 
8-15 mg 
8-15 mg 
15-30 mg 
20 mg 
 
60mg/m
2
/d 
1.000mg/m
2
/injection 
30mg/m
2
/injection 
 
 
D1 – D14 continuous, reduce dose - off D21 
D1-10-20-30 
D1-8-15 
D1-8-15 
D2-11-21-31 
D3-5-8-10-12-15 
D1-10-20-30 
D2 or D3-30 
D1-29 
D1-29 
D1-29 
 
D29 – D49 continuous 
D29 
D29-30/ D36-37/ D43-44 
 
 
A3/B/T 
A1/A2 
A3/B/T 
A3/B/T 
A1/A2 
A3/B/T 
A1/A2 
Single A1/A2 or Single A3 
Triple B1/T1 
Triple B1/T1 
Triple B1/T1 
 
 
Maintenance 
Re-induction 
- Dexamethasone  (oral or IV) 
- Prednisone  (oral or IV) 
- Vincristine  (IV) * 
 
 
6mg/m
2
/d 
40mg/m
2
/d 
1,5mg/m
2
/injection (2mg max) 
Month 1-24 
Month 1-12 
D1-D5 continuous 
D1-D7 continuous 
D1 
 
 
A 
B/T 
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Phase/Drugs Daily Dose Days of Application per Element Note of toxicity/dose 
Maintenance 
- MTX  (oral) 
 
- Mercaptopurine  (oral) 
- MTX  (IT) 
- Aracytine  (IT) 
Depomedrol  (IT) 
 
25mg/m
2
/week 
 
75mg/m
2
/d 
8-15 mg 
15-30 mg 
20 mg 
 
3 weeks/month  (M1-12) 
4weeks/month  (M13-24) 
M1-24 
D1/M1-3 
D1/M1-3 
D1/M1-3 
 
 
Higher toxicity 
Single in A 
Triple in B/T 
Triple in B/T 
Dose of MTX and Aracytine in IT depend on age.  
Subgroups (A1/A2/A3 or B1/B2 or T1/T2) divide at D21 or D35 of induction phase. 
The assignment to risk group in the FRALLE 2000 protocol with specified treatment according to age, WBC count at diagnosis, French- American-British 
(FAB) classification (L1/L2/L3) , and result of fow cytometry. Patients were stratified into three treatment groups: 
- Standard risk (SR) group: FRALLE 2000-A (A1/A2/A3) 
 Patient with ALL, B-cell line, L1 or L2 
 Age > 1year or  < 10years 
 WBC at diagnosis < 50.000/mm³ 
 Trisomy 21 
- Hight risk (HR) group:  FRALLE 2000-B (B1/B2) 
 Patient with ALL, B-cell line, L1 or L2 
 Age > 10 years 
 WBC at diagnosis ≥ 50.000/mm³  
 Detectable CNS involvement 
 Present of t(9;22) or t(4;11) or hypodiploide ≤ 44 chromosomes 
 Present of BCR-ABL or MLL arrangement 
27 
 
- Very high risk (VHR) group: FRALLE 2000-T (T1/T2) 
Patient with ALL, T-cell line, L1 or L2 
FAB classification of ALL and features of blasts: 
 Type L1:  Small cells with scant cytoplasm; nucleoli indistinct and not visible 
 Type L2: Large, heterogeneous cells with moderately abundant cytoplasm; clefting and 
indentation of nucleus; large and prominent nucleoli. 
 Type L3: Large cells with moderately abundant cytoplasm; regular, oval-to-round 
nucleus; prominent nucleoli; prominent cytoplasmic basophilia and cytoplasmic vacuoles. 
Methotrexate 
MTX (4-amino-10-methylpteroyl-L-glutamic acid) is an analogue to the folic acid antagonist 
aminopterin (Fig.3), the first drug to induce remissions in children with ALL (Schornagel and 
McVie 1983). Today MTX is the most widely used drug in chemotherapy and is used 
throughout the 2-2½ years of therapy in childhood ALL. Although the optimal dosage is still 
under active investigation, high dose methotrexate (HD-MTX) is commonly given as 
consolidation therapy, and low-dose oral MTX (LD-MTX) is given in continuation therapy in 
most childhood ALL treatment protocols. MTX has increased affinity for its target enzymes 
when MTX is polyglutamated intracellularly and the polyglutamated MTX is intracellularly 
retained far longer than the administered monoglutamated MTX. The antileukemic effect of 
MTX is well documented (Evans, Relling et al. 1998, Burke, Estlin et al. 1999) and it has been 
shown that intracellular and extracellular concentrations of MTX and its active polyglutamated 
metabolites are significant for the antileukemic effect and cure rate (Masson, Relling et al. 
1996). Treatment efficiency is assessed by the number of lymphoblasts in BM (MRD) and 
outcome (van Dongen, Seriu et al. 1998, Coustan-Smith, Sancho et al. 2000, Schmiegelow, 
Nyvold et al. 2001). 
 
Figure 3: Folic acid and methotrexate only differ in an amino and a methyl-group. 
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Tetrahydrofolic acid itself is synthesized in the cell from folic acid with the help of an enzyme 
folic acid reductase. Methotrexate looks a lot like folic acid. So methotrexate binds to it quite 
strongly and inhibits folic acid reductase which is responsible for the conversion of folic acid 
to tetrahydrofolic acid. 
Methotrexate metabolism pathway 
Uptake of MTX into ALL cells is primarily mediated by reduced folate carrier (RFC) (Solute 
Carrier Family 19, member 1 (SLC19A1)), whereas efflux of MTX is mediated by ATP-
binding cassette transporters (ABC-transporters) (Hooijberg, Broxterman et al. 1999, Zeng, 
Chen et al. 2001, Chen, Lee et al. 2002). Once inside the cell, MTX is quickly converted into 
poly (γ-glutamate) forms methotrexate polyglutamates (MTXPGs), a reaction catalyzed by 
folylpolyglutamate synthetase (FPGS) (McGuire, Hsieh et al. 1980). Compared to the parental 
drug, MTXPGs (especially long-chain MTXPGs) are retained longer in cells because they are 
not readily effluxed by ABC-transporters (Chabner, Allegra et al. 1985, Banerjee, Mayer-
Kuckuk et al. 2002). The ability of ALL cells to form and accumulate MTXPGs has been 
shown to influence treatment response and outcome in childhood ALL (Whitehead, Rosenblatt 
et al. 1990, Barredo, Synold et al. 1994, Masson, Relling et al. 1996). 
MTX and MTXPGs exert their effect by inhibiting enzymes essential for thymidylate synthesis 
and de novo purine synthesis, which will affect deoxyribonucleic acid (DNA) synthesis and 
cellular proliferation by primarily inhibiting the enzyme dihydrofolate reductase (DHFR), 
leading to depletion of 5-10 methylene tetrahydrofolic acid and N-10 formyl tetrahydrofolic 
acid. As these tetrahydrofolates function as co-factors to one-carbon transfer reactions, various 
configurations and synthetic reactions, which are dependent on one-carbon addition, are 
inhibited. Both the purine de novo synthesis and the thymidylate synthesis are dependent on 
one-carbon addition. For example, the thymidylate synthesis receives a one-carbon group from 
5,10-methylene tetrahydrofolate to deoxyuridine monophosphate (dUMP) for the conversion to 
Deoxythymidine monophosphate (dTMP), one of the precursors essential for DNA-synthesis. 
In this process, the 5,10-methylene tetrahydrofolate is oxidized to dihydrofolate and DHFR 
would, if not inhibited by MTX and MTXPGs, reduce it to tetrahydrofolate again. The 
inhibition of DHFR also prevents DHFR from reducing MTXPGs to MTX. As MTXPGs is 
retained longer inside the cell, the accumulation of MTXPGs will extend the toxic effect to the 
cell. MTXPGs inhibits MTHFR, TS, glycinamide ribonucleotide transformylase (GAR-Tase) 
and aminoimidazole carboxamide ribonucleotide transformylase (AICAR-Tase), all essential 
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for either the thymidylate synthesis or the de novo purine synthesis (Schornagel and McVie, 
1983; Schroder, 1990). It is also likely that MTX has inhibitory effects on the intracellular 
transport of glucose. MTX kills cells during the S phase of the cell cycle and has the highest 
efficacy on rapidly dividing cells. In high-dose MTX treatment, the cells are depleted and the 
patient will die, if leucovorin rescue is not given.  
Leucovorin (folinic acid), which is also known as 5-formyl tetrahydrofolate, is an active form 
of one of vitamins known as folates. The folate coenzymes (including Folinic Acid and L-5-
MTHF) are responsible for the following important metabolic functions and benefits: 
Formation of purines and pyrimidines, formation of the amino acid methionine from 
homocysteine (Vitamin B12 as methylcobalamin), formation of heme, and formation and 
maturation of red and white blood cells… Leucovorin is a faster acting and stronger form of 
folic acid (also known as vitamin B9). Leucovorin bypasses the metabolic block caused by 
MTX, thereby permitting normal cells to synthesize thymidylate and other compounds. It 
should be noted that failure to administer leucovorin in the right dose at the right time can be 
fatal.  
 
Figure 4: Mechanism of action of intracellular methotrexate (based on source Medecine/Sciences-
vol 23- 11/2007). 
ABCG2= ATP-binding cassette (ABC) family especially G2; CCND1= cyclin D1; DHF= 
dihydrofolate; DHFR= dihydrofolate reductase; dTMP= deoxythymidine monophospate; 
dUMP= deoxyuridine monophospate; FPGH= folylpolyglutamate synthetase; GGH= γ-
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glutamyl hydrolase; pRB= Retinoblastoma protein; MRP 1-5= multidrug resistance proteins 1-
5; MTHFD1= methylenetetrahydrofolate dehydrogenase; MTHFR= methylenetetrahydrofolate 
reductase; MTX= methotrexate; MTXPG= methotrexate polyglutamates; MS= methionine 
synthase; RFC1= reduced folate carrier; THF= tetrahydrofolate; TSER= thymidylate synthase.  
MTX enters cells through the RFC1 or other transport systems. After entering the cell, MTX is 
transformed to MTXPG by the enzyme FPGH. FPGH increases the efficacy of methotrexate. 
Glutamates can be removed by GGH and MTX monoglutamate is rapidly effluxed from the cell via 
membrane transporters of the ATP-binding cassette (ABC) family, especially ABCC1-4 and ABCG2. 
The main intracellular target of MTX is DHFR, inhibition of which results in accumulation of DHF and 
depletion of cellular folates. The addition of glutamate residues to methotrexate also increases its 
affinity for other target enzymes (TSER and DHFR). Other enzymes that are indirectly affected by 
methotrexate are MTHFR, MTHFD1, CCND1. 
Individualisation of therapy 
Traditionally, the same kind of drug is given to patients with the same disease, and the dose is 
based on the patients’ weight or body surface area (m2). However, response to treatment can 
vary greatly, even though they all are treated with the same drug and the same dose per square 
meter (Eichelbaum, Ingelman-Sundberg et al. 2006). This variability in individual response can 
be caused by non-genetic factors, such as age affecting kidney function, liver function, 
environment, food, and concomitant diseases. However genetics is responsible for typically 15 
to 30%, and in rare cases up to 95%, of individual differences in drug metabolism and 
treatment effect. These genetic differences can affect both pharmacokinetics (e.g 
drugmetabolising enzymes) and pharmacodynamics (e.g. drug targets or target related proteins) 
and thus affect both efficacy and toxicity (Nebert, Zhang et al. 2008). Patients with the same 
diagnosis may respond in different ways to the same drug. In the best case the prescribed drug 
is not toxic and beneficial, but in some cases it can be also not beneficial. In other cases the 
treatment can be toxic, but beneficial. The worse occurrence is when the drug is toxic and also 
not beneficial (Figure 5). 
Through the use of pharmacogenetics, physicians will be able to profile variations between 
individual’s DNA to predict responses to a particular medicine. Pharmacogenetics will have 
impact on medical care and medical aid at multiple levels (Roses 2000). Moreover, 
pharmacogenetic testing may provide the first example of a mechanism whereby DNA based 
testing can be applied to populations (Wolf, Smith et al. 2000). The intersection of 
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pharmacogenomics and medicine has the potential to yield a new set of molecular diagnostic 
tools that can be used to individualize and optimize drug therapy (Evans and Relling 2004). 
 
Figure 5: Individualized therapy means the use of pharmacogenomics to select the right drug for the 
right person prior to medication prescription (base on www.dana-farber.org) 
Personalized medicine recognizes that individual patients may react in very different ways to the same 
treatment given for the same problem. The goal is to tailor therapies based on a patient's DNA profile. 
Personalized tumor molecular profiles, tumor disease site and other patient characteristics are then 
potentially used for determining optimum individualized therapy options. 
Pharmacogenetics and pharmacogenetic terms    
Individual variation in response to drugs is a substantial clinical problem. Individuality in drug 
response can be inherited. The genetically determined variability in drug response defines the 
research area known as pharmacogenetics. Pharmacogenetics has evolved in the past 50 years 
to a major driving force of clinical pharmacology. The first concept of pharmacogenetics was 
originated from Motulsky in 1957 (Motulsky 1957). The term pharmacogenetics was suggested 
by Vogel in 1959 (Vogel 1959), and the first book on the subject was written by Kalow (Tang 
and Endrenyi 1998). The first molecular defect was identified by Frank Gonzalez in the late 
1980s (Gonzalez, Skodat et al. 1988). The term pharmacogenetics is used to cover both 
germline and somatic predictors of drug response (Goldstein, Tate et al. 2003). One of the main 
directions in development of pharmacogenetics is identifying genes and allelic variants of 
genes that affect our response to drugs (Wolf, Smith et al. 2000). To date, polymorphisms of 
genes encoding drug metabolism enzymes, drug transporters, and drug receptors, which are 
involved in drug responses, have been reported and in some of them the association between  
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pharmacodynamics and drug efficacy has been clarified (Evans and Relling 1999, Goldstein, 
Tate et al. 2003). 
Pharmacogenetics is the study of variability in drug response due to heredity. The commonest 
form of genetic variation is the single nucleotide polymorphism (SNP) where a single 
nucleotide base is altered or deleted or an additional nucleotide base inserted. It is estimated 
that such a change (or polymorphism) occurs every 500–1000 bases in the human gene 
(Pirmohamed 2001). SNPs may occur within the coding or non-coding region of the gene. 
SNPs within the coding region may lead to changes in the amino acid produced (known as a 
non-synonymous polymorphism). SNPs within the non-coding region may still affect gene 
transcription, gene splicing or RNA stability. Given the rapid advances in high-throughput 
genotyping it is now possible to screen large numbers of these polymorphisms throughout the 
human genome that may influence drug response. This review will highlight the possible 
pharmacogenetic targets for MTX by considering its metabolism and mechanisms of action. 
There are differences between pharmacogenetics and pharmacogenomics. Accordingly, most of 
scientists use pharmacogenetics to depict the study of single genes and their effects on 
interindividual differences in drug metabolizing enzymes, and pharmacogenomics usually used 
in broader context, to depict the study of not just single genes, but the functions and 
interactions of all genes in the genome in the overall variability of drug response, whether this 
is caused by pharmacokinetics, pharmacodynamics or both. Some have distinguished between 
pharmacogenetics and pharmacogenomics on the basis of either the type of genomic 
information or the quantity (Goldstein, Tate et al. 2003). The differences between the 
pharmacogenetics and pharmacogenomics are the initial approach of the science. 
Pharmacogenetics is based on an unexpected drug response result and looks for a genetic 
cause, while pharmacogenomics looks for genetic differences within a population that explain 
certain observed responses to a drug or susceptibility to a health problem (www.genetics.edu.au). 
To summarize, classical pharmacogenetics has searched the genes for an abnormal drug 
response of proven clinical value, whereas pharmacogenomics presently and in the future will 
search the bearing if any of known genes, SNPs or haplotypes. 
The Role of Ethnicity in Pharmacogenetics      
Genetic differences between people contribute to interindividual differences in the response to 
many drugs. Findings of the Human Genome Project cleared that 99.9 % of the information in 
the estimated 20.000 human genes is identical from one person to the next. The small 
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differences in the remaining 0.1% of genes are the key to each individual 
(www.genetics.edu.au). Very often the variability in DNA consists of only one nucleotide base 
change, and if this occurs in more than 100 subjects at a given position in the DNA, it is 
referred to as a single nucleotide polymorphism. SNPs make up about 90% of all human 
genetic variation. In 2008, about 12 million SNPs and a large amount of other types of genetic 
variation were known in the human genome (Brockmöller and Tzvetkov 2008). The remainder 
of the variation is caused by insertions, deletions, tandem repeats and microsatellites (Marsh 
and McLeod 2006). 
It is known, that many polymorphisms that influence drug response and which probably 
contribute significantly to phenotypic variation in drug response have significant allele 
frequency differences among racial or ethnic groups (Evans and Relling 1999, Tate and 
Goldstein 2004, Engen, Marsh et al. 2006). Recent studies report differences between African 
and non-African population groups in the structure of sequence variation in the human genome 
(Tishkoff and Verrelli 2003). 
Geographic patterns of genetic variation, including variation at drug metabolizing enzyme loci 
and drug targets, indicate that geographic structuring of inter-individual variation in drug 
response may occur frequently. This geographic distribution of certain variants has highlighted 
the possible importance of average differences in drug response across populations (Wilson, 
Weale et al. 2001). For this reason we need to take into account not just differences between 
the genotypes of individuals, but the differences in genotypes between population groups of 
different origin and the substantial variation between the five main racial groups, which are 
based on continental ancestry (Daar and Singer 2005). 
In conclusion, understanding of human genomic variation and its application in 
pharmacogenetics might shift our focus away from interindividual differences towards 
interpopulation differences (Daar and Singer 2005). Thus race or ethnicity will usually be a far 
inferior guide to response than direct determination of the underlying genetic variant (Need, 
Motulsky et al. 2005). 
Drugs interacting with MTX 
Delayed renal excretion can be caused by concurrent use of drugs in which reduce renal blood 
flow, are nephrotoxic or are weak organic acids (e.g. nonsteroidal anti-inflammatory agents, 
cisplatin and aspirin/piperacillin, respectively) and can lead to severe myelosuppression 
(Thyss, Kubar et al. 1986). 6-MP is used in ALL therapy together with MTX and gives a 
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synergistic in-vivo effect on both toxicity and efficacy (Bökkerink, Bakker et al. 1988, 
Schmiegelow, Schrøder et al. 1994, Schmiegelow, Schrøder et al. 1995, Schmiegelow and 
Bretton-Meyer 2001, Nygaard and Schmiegelow 2003). 
Thiopurines 
Both azathiopurine (AZA) and 6-MP need to undergo extensive metabolic transformations 
(Figure 6) before they can exert their immunosuppressive activity, as both substances have no 
intrinsic activity. Once absorbed, approximately 90% of the absorbed AZA undergoes a rapid 
non-enzymatic conversion in the liver, yielding 6-MP and methyl-4-nitroimidazol. The 
remaining 10% of AZA, which is also cleaved non-enzymatically, yields amongst others 
hypoxanthine and methyl-4-nitro-5-thioimidazol. The absorption of AZA is incomplete and 
(interindividually and intraindividually) variable resulting in a wide range of bioavailability 
from 16-72% (Schwab and Klotz 2001). Subsequently, 6-MP is metabolized by three 
competing enzyme systems, xanthine oxydase (XO), TPMT and hypoxanthine guanine 
phosphoribosyltransferase (HPRT). The enzyme XO catalyses the reaction of 6-MP to the 
pharmacologically inactive metabolite 6-Thiouric-acid, whereas the enzyme TPMT methylates 
6-MP into 6-methyl MP. The HPRT enzyme is responsible for the conversion into 6-
thioinosine monophosphate (6-TIMP). Subsequently, 6-TIMP can be further transformed by 
inosine monophosphate dehydrogenase (IMPD) into 6-thioxanthylic acid (6-TXMP), which 
subsequently is converted via guanosine monophosphate synthetase to 6-thioguanylic acid (6-
TGMP). The 6-thioguanine nucleotides (6-TGN) have a half-life of approximately 5 days with 
a wide range of 3-13 days (Schwab and Klotz 2001). The different 6-TGN may all be 
methylated by TPMT. The metabolite 6-TIMP can be methylated via TPMT to form 6-methyl 
TIMP, 6-methyl thioinosine diphosphate (6-methyl TIDP) and 6-methyl thioinosine 
triphosphate (6-methyl TITP). The latter three metabolites are the so-called 6-MMPR. 6-
Thioinosine-monophosphate can also be phosphorylated via monophosphate kinase (MPK) to 
6- TIDP, and subsequently, via diphosphate kinase (DPK) to 6-TITP, and ultimately back to 6-
TIMP following an enzymatic reaction with inosine triphosphatase (ITP) pyrophosphatase. 6-
TGN are considered as the pharmacologically active end-metabolites.  6-TGN are considered 
as the pharmacologically active end-metabolites. In the classical immunosuppressive theory, 
the mode of action is specifically ascribed to antimetabolic (cytotoxic) pathways. The 6-TGN, 
as a result of their structural similarity to the endogenous purine bases, are incorporated into 
DNA or Ribonucleic acid (RNA) as fraudulent bases, resulting in strand breakage and 
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interference with de novo synthesis of proteins and nucleic acids (Fairchild, Maybaum et al. 
1986, Marinaki, Ansari et al. 2004). 
 
Figure 6: Metabolization of thiopurine based drugs Azathiopurine (base on Article “Assessment of 
Thiopurine S-Methyltransferase Activity in Patients Prescribeb Thiopurines: A Systematic Review”. 
Ann Intern Med.2011). 
AO = aldehyde oxidase; AZA = azathiopurine; DPK= diphosphate kinase; GD = guanine deaminase; 
HGPRT = hypoxanthine guanine phosphoribosyltransferase; IMPDH = inosine monophosphate 
dehydrogenase; ITPA= inosine triphosphatase; MP = mercaptopurine; MPK= monophosphate kinase; 
TG = thioguanine; TGMP = thioguanine monophosphate; TGN = thioguanine nucleotides; TIDP= 
thioinosine diphosphate; TIMP = thioinosine monophosphate; TITP= thioinosine triphosphate;TMPT = 
thiopurine S-methyltransferase; TXMP = thioxanthylic acid; XO = xanthine oxidase.  
AZA is degraded to 6-MP and nitromethyl-imidazole, via a non-enzymatic step. Three competing 
enzymes metabolize 6-MP. XO inactivates 6-MP to 6-Thiouric acid. TPMT methylates 6-MP into 6- 
methyl MP, this metabolite is associated with hepatotoxicity. By HPRT, 6-MP is catalyzed to 6-TIMP, 
then via IMPDH to 6-TXMP, ultimately leading to the pharmacologically active 6- TGN (consisting of 
6-TGMP, 6-TGDP and 6-TGTP) via the enzyme guanosine monophosphate synthetase. 6-TIMP can 
also be methylated to 6-methyl TIMP, 6- methyl TIDP and 6-methyl TITP. In a normal useless cycle, 6-
TIMP is phosphorylated by MPK to 6-TIDP, subsequently by DPK to 6- TITP and ultimately back to 6-
TIMP due to ITPA. When ITPase activity is impaired or lacking, 6-TITP accumulates. 6-TG is directly 
converted by HPRT to 6- TGN. TPMT metabolize 6-TG to 6-methylthioguanine (6-methyl TG). 
Guannine deminase (GD) or aldehyde oxidase (AO) metabolize 6-TG to 6- Thiouric acid. ITPA has no 
known role in the metabolism of 6-TG. 
The thiopurine antimetabolites MP and TG, analogues of the purine nucleosides hypoxanthine 
and guanine, are key components in childhood ALL treatment protocols. MP or TG are used 
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during induction consolidation treatment as well as in maintenance therapy. After uptake via 
nucleoside transporters, these medications are metabolized into active cytotoxic TGNs and 
cytotoxicity occur mainly by incorporation of TGNs into DNA or RNA resulting in cell cycle 
arrest and apoptosis (Relling, Hancock et al. 1999). TPMT and ITPA are involved in the 
metabolism of 6-MP. Polymorphisms in the ITPA gene have been associated with neutropenia 
and thrombocytopenia during thiopurine therapy (Stocco, Cheok et al. 2009). 
Linkage disequilibration 
Linkage disequilibration is the phenomenon where two or more genetic variant combinations 
are inherited together, resulting in fewer haplotypes than expected. In humans this is often seen 
in genetic variants with a small physical distance between loci, resulting in fewer meiotic 
recombinations between the genetic variants. 
Polymorphism  
Polymorphism (Greek: multiple forms) is the phenomenon of alternative DNA sequences 
between individuals at a locus in the genome. There are different types of polymorphisms: 
single base polymorphism, deletions, or insertions of a section of DNA, the latter includes 
repeated sequences. The majority of human sequence variations are due to substitutions that 
have occurred once in the history of mankind at individual base pairs. SNP is the most common 
form of polymorphisms, found in approximately 1 of every 600 base pairs (Patil, Berno et al. 
2001). In polymorphisms where a sudden variant causes diseases, the variant is often referred 
to as a mutation. The most frequent variant, which obviously does not cause disease, is called 
wild type. In pharmacogenetics a variant can be most frequent in one ethnic population but not 
in another ethnic population, hence the term wild type is avoided in the thesis. Instead, the 
specific nucleotides from each allele are mentioned (e.g. 3435CC, 3435TT or 3435CT, if the 
variant is heterozygous).  
CCND1 G870A polymorphism 
The CCND1 gene (located on chromosome 11 q13) (Figure 7) codes for CCND1, which is a 
key protein for the cellular division, as it regulates the transition from the G1 to the S phase of 
the cell cycle. Uncontrolled cell proliferation is one of the hallmarks of cancer. The cell cycle 
is the machinery that governs proliferation and growth of cells, thus, alteration in genes 
regulating the cell cycle could predispose to cancer. CCND1 has a critical role in control of cell 
cycle G1 to S phase transition. CCND1 coding gene CCND1 has a commonly occurring G to A 
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polymorphism (G870A, Pro241Pro) at position 6962 (rs 603965) in exon 4. Overexpression 
and deregulation of this gene may lead to abnormalities in the cell cycle resulting in 
carcinogenesis (Knudsen, Diehl et al. 2006). It has been postulated that the A allele results in a 
higher level of mRNA (transcript-b), encoding for a protein with an altered C-terminal domain, 
with enhanced cell transformation activity and possible prolonged half-life (Sobti, Kaur et al. 
2006). This polymorphism produces two alternatively spliced forms of a transcript with 
varying stability and enzymatic activity. The protein product of the CCND1 A allele has higher 
enzymatic activity and is hypothesized to be more stable than the product of the G allele 
(Betticher, Thatcher et al. 1995). 
While CCND1 870 AA genotype has been reported to increase the risk for childhood ALL in a 
Chinese population (Hou, Wang et al. 2005), it has also been associated with an increased 
MTX resistance with EFS reduction (Costea, Moghrabi et al. 2003, Costea, Moghrabi et al. 
2006). CCND1 is the major D Cyclin in most cell types.  All 3 Cyclin D molecules act in late 
G phase, just before entry into S phase. Many tumors have high CCND1 levels without 
amplification or mutation of the CCND1 structural gene. In blasts from patients with acute 
lymphocytic leukemia, resistance mechanisms found are decreased uptake and increased 
DHFR activity. A major cause of intrinsic resistance to MTX in soft tissue sarcoma cells and in 
acute myelocytic leukemia appears to be a lack of drug retention, due mainly to low levels of 
polyglutamylation. A novel association between lack of the retinoblastoma protein and intrinsic 
MTX resistance has been found. This has been attributed to an increase in DHFR activity, due 
to an increased rate of transcription of this gene, stimulated by an increase in levels of free 
E2F, not sequestered by hypophosphorylated retinoblastoma protein. CCND1 A870G 
polymorphism modulates the ratio of CCND1 mRNA isoforms, and the transcript associated 
with the A allele results in the protein with a longer half-life. CCND1 AA870 were previously 
associated with worse ALL outcomes (Bertino, Göker et al. 1996).  
The reported prevalence of 870AA homozygotes in Caucasian and in Asian ALL children 
ranges from 22.3 to 25.7% and 32.4 to 38%, respectively (Phaichitchinda 2005, Onay, 
Aaltonen et al. 2008, Pabalan, Bapat et al. 2008, Yang, Lin et al. 2010). 
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(a)                    (b)  
 
Figure 7: CCND1 gene. (a) CCND1 gene – chromosome 11 (base on http//: www.ghr.nlm.nih.gov)   
(b) CCND1 protein (base on en.wikipedia.org) 
CCND1 G870A polymorphism and cancer risk 
The CCND1 G870A A allele has been reported to be associated with increased risk for several 
cancers, including colorectal, esophageal, cardiac, bladder, head and neck, lung, prostatic, and 
renal cell carcinomas as well as leukemia (Knudsen, Diehl et al. 2006). 
The results have not been entirely consistent since some studies have shown no risk and 
increased risk for cancer has even been reported for the GG genotype. Thus, the effect of this 
polymorphism may vary in distinct tumor types, although differences in study designs can also 
explain some of the discrepancies. The highest risks have, however, been reported in most 
studies for the AA genotype. The relative risks have typically been modest, which can in part 
be expected for a common allele such as the A allele in CCND1 polymorphism. The cancer 
risk with this low-penetrance variant could be modified by polymorphisms in other genes or 
environmental factors (Buch, Zhu et al. 2005, Shu, Moore et al. 2005). 
Cell cycle 
The human cell cycle is a firmly controlled machinery that regulates cell entry into mitosis and 
DNA replication, and thus, cell division. Cell cycle consists of different phases: G1 phase 
(preparation for DNA synthesis), S phase (DNA synthesis and replication), G2 phase (the 
second gap), and M phase (mitosis) (Figure 8). G0 (quiescence) is a biochemically different 
resting phase, where cells are kept in the absence of proliferation stimuli, but from which cells 
upon growth factor stimulation can re-enter into the active cell cycle. As cells receive enough 
environmental proliferation stimuli, they move from G1 to S phase. This G1/S transition is 
considered irreversible (Sherr 1996). The G2 phase is important for DNA replication and for 
the correction of errors in replication. 
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Cyclin-dependent kinases (CDKs) regulate the cell cycle and changes between different 
phases. CDK levels remain relatively constant throughout the cell cycle, but they are activated 
and inactivated by periodic changes in levels of their binding proteins. Cyclins are cell cycle 
regulator proteins that activate cell cycle progression by binding to CDKs. Active cyclin-CDK 
complexes drive phosphorylation cascades throughout the cell cycle. CCND1-CDK4/6 and 
cyclin E-CDK2 complexes act predominantly on G1 phase, cyclin A-CDK2 on S and G2 
phases, and cyclin B1-CDK1 on G2 phase and mitosis. CKIs consist of large amount of 
inhibiting proteins, e.g. INK4 group inhibitors CDKN2A (p16 and p14), CDKN2B (p15), 
CDKN2C (p18), and CDKN2D (p19), and the second group of CIP/KIP (cyclin-dependent 
kinase inhibitory protein/kinase inhibitor protein) inhibitors CDKN1A (p21) and CDKN1B 
(p27) (Sherr and Roberts 1999). Inhibitors of kinase 4 (INK4s) bind to CDK4 and CDK6 to 
prevent their association with CCND1. CIP/KIP inhibitors do not affect cyclin binding, but 
form complexes with the G1/S transition CDKs. CKIs allow the cell cycle to be controlled at 
multiple levels. 
The most important target of cyclin-CDK phosphorylation is the pRb and other retinoblastoma 
family proteins such as p107 and p130. Active pRb represses the transcription factors essential 
for G1/S transition. Thus, pRb is a negative cell growth regulator. Upon stimuli of proliferation 
factors, pRb becomes inactivated and transcription factors needed for G1/S transition are 
activated. The pRb hyperphosphorylation disrupts its association with E2F, and activated E2F 
mediates transcriptional activation required for G1 progression. CCND1-CDK4/6 complex is 
upregulated early after mitogenic stimuli and initiates the phosphorylation and inactivation of 
pRb (Baldin, Lukas et al. 1993). Cyclin E-CDK2 complex becomes activated later and is 
necessary in pRb phosphorylation in late G1 phase as well as in events leading to DNA 
synthesis (Sheaff, Groudine et al. 1997, Caldon, Daly et al. 2006). Recent data suggests that 
also the cell cycle reentry from G0 to G1 phase is regulated by specific retinoblastoma family 
proteins in association with specific E2F transcription factors. Cyclin C/CDK3 complex 
controls the pRb suppression at this phase and seems to be critical in promoting cell exit from 
the quiescent G0 phase (Ren and Rollins 2004). The G0 to G1 transition, however, is 
incompletely understood.  
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Figure 8: Cell cycle of cellular (based on www.bdbiosciences.com) 
The cell cycle has two major phases: interphase, the phase between mitotic events, and the mitotic 
phase, where the mother cell divides into two genetically identical daughter cells. Interphase has three 
distinct, successive stages. During the first stage called G1, cells "monitor" their environment, and 
when the requisite signals are received, the cells synthesize RNA and proteins to induce growth. When 
conditions are right, cells enter the S stage of the cell cycle and "commit" to DNA synthesis and 
replicate their chromosomal DNA. Finally, in the G2 phase, cells continue to grow and prepare for 
mitosis. 
GGH C452T polymorphism 
GGH (located on chromosome 8p12.3) (Figure 9) is a lysosomal peptidase that catalyzes the 
removal of ɣ -linked polyglutamates of folates and anti-folates such as MTX, thus allowing 
folates to be exported from the cells or converting long-chain MTXPGs into short-chain 
MTXPGs and ultimately to MTX (Rhee, Lindau-Shepard et al. 1998, Panetta, Wall et al. 
2002). Long-chain MTXPGs, which is the active form of MTX, directly blocks folate-
dependent enzymes and leads to inhibition of de novo thymidine and purine synthesis, arresting 
DNA replication and causing cell death (Rhee, Lindau-Shepard et al. 1998, Cheng, Wu et al. 
2004). MTXPGs cytotoxicity and efficacy are related to its cellular concentration and 
persistence (GALIVAN 1980, Koizumi, Curt et al. 1985). It has been previously shown that the 
T variant allele of GGH may result in decreased GGH activity, hence increasing intracellular 
MTXPGs. These observations suggest that GGH C452T polymorphism monitoring could be 
used to predict side effects and resistance to MTX (Hayashi, Fujimaki et al. 2007). Little is 
known however about MTX resistance in relapsed childhood ALL. Cells from relapsed 
precursor-B ALL have been shown to be threefold more resistant to MTX than those from 
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newly diagnosed ALL (Rots, Pieters et al. 2000). It can therefore be hypothesized that GGH 
C452T polymorphism could play a role in ALL relapse through its interaction with MTX 
metabolism. While the reported frequency of the GGH 452CT variant allele in Caucasian and 
in Asian ALL patients varies from 6 to 15.5% and 10 to 19%, respectively, it ranges between 0 
and 4% or 0.4 and 1.5% for the GGH 452TT homozygote variant in both ALL populations, 
respectively (Hayashi, Fujimaki et al. 2007, Organista-Nava, Gómez-Gómez et al. 2010, Yang, 
Lin et al. 2010, Tiseo, Giovannetti et al. 2012). 
(a)  
 
 (b)  
Figure 9: GGH gene. (a) GGH gene – chromosome 8 (base on en.wikipedia.org) (b) Gamma-glutamyl 
hydrolase protein (base on en.wikipedia.org) 
ITPA A94C  polymorphism 
ITPA (located on chromosome 20p13) (Figure 10) catalyzes pyrophosphohydrolysis of ITP to 
IMP and deficiency of this enzyme leads to the abnormal accumulation of ITP (Kudo, Saito et 
al. 2008). It has been predicted that 6-MP is activated via a 6-TIMP intermediate and thus, 
toxic 6-TITP accumulates in ITPase-deficient patients on thiopurine drug treatment. In the 
ITPA gene, we detected a known nonsynonymous SNP, namely, 94C>A (Pro32Thr, 
rs1127354).  
Interindividual differences in the therapeutic or toxic effects of 6-MP can be explained in part 
by variation in the formation of active metabolites. This variation is due to genetic 
polymorphisms in the genes encoding enzymes involved in thiopurine metabolism. Recent 
reports provide evidence for association between the ITPA 94CA or 94AA polymorphism and 
the occurrence of adverse drug reactions in patients treated with thiopurines (Sumi, Marinaki et 
al. 2002, Marinaki, Ansari et al. 2004). ITPA shows genetically determined polymorphic 
activity. The ITPA-C94A transversion reduces ITPA enzymatic activity to 25% and ~0% in 
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heterozygote and homozygote carriers, respectively (Stocco, Cheok et al. 2009). For patients 
without dose reduction of 6-MP according to TPMT genotype, those with ITPA-94AC/AA 
genotype were reported to have a higher probability of severe febrile neutropenia (Stocco, 
Cheok et al. 2009). Conversely, TPMT has been shown to have a higher impact than ITPA on 
6-MP toxicity when the dose of 6-MP was not adjusted for TPMT phenotype (Stocco, Crews et 
al. 2010). In line with these data, it has been suggested that ITPA variants may have stronger 
impact in Asians than in Caucasians as the prevalence of TPMT*3A variant in Asians is lower 
than in Caucasians whereas the reverse is observed for the prevalence of ITPA variants (Marsh 
and Van Booven 2009, Kim, Kang et al. 2012). In contrast, Kim et al. showed that toxicity of 
6-MP was related neither to TMPT nor to ITPA polymorphisms, but reported a lower event-
free survival (EFS) rate in patients carrying the ITPA-94AC/AA genotypes (Kim, Kang et al. 
2012). ITPA effect on RFS remains so far unclear. The prevalence of the ITPA-C94A 
transversion varies with ethnicity, ranging from 3.3 % in Africans, to 8.3 % in Caucasians, 11-
19 % in Asians (Marsh and Van Booven 2009, Stocco, Cheok et al. 2009), and 3% in Chilean 
(Farfan, Salas et al. 2014). 
 
 
(a)  
(b)   
MTHFR polymorphism 
MTHFR (located on chromosome 1p36.3) (Figure 11) catalyzes the reduction of 5,10-
methylene-THF to 5,10-methyl-THF which is the predominant circulating form of folate and 
acts as the carbon donor for remethylation of homocysteine to methionine (Aplenc, Thompson 
et al. 2005). MTHFR plays a key role in determining the amount of folate available in the cell 
for DNA synthesis and methylation. The accumulation of 5,10-methyl-THF resulting from the 
MTHFR genetic polymorphism may play a role in MTX response (Giovannetti, Ugrasena et al. 
2008). Specific MTHFR genotypes have allegedly been associated with MTX toxicity in 
(a) ITPA gene – chromosome 20 (base on 
en.wikipedia.org) (b) Inosine triphospatase protein 
(base on en.wikipedia.org) 
Figure 10: ITPA gene 
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leukemia patients (Robien, Schubert et al. 2006), and with an increased risk of relapse in 
pediatric ALL patients (Krajinovic, Lemieux-Blanchard et al. 2004). The prevalence of 
MTHFR C677T and the A1298C variant alleles varies with ethnicity: the prevalence of 677TT 
ranges between 9 to 11% and 2.5 to 8.5% in Caucasian and Asian ALL children, respectively 
(de Jonge, Hooijberg et al. 2005, Giovannetti, Ugrasena et al. 2008, They-They, Hamzi et al. 
2009), versus 9% to 16.5%, and 0% to 9%, respectively, for the prevalence of 1298CC 
(Krajinovic, Lemieux-Blanchard et al. 2004, de Jonge, Hooijberg et al. 2005, Sirachainan, 
Wongruangsri et al. 2008). 
(a)
 
                             (b)  
Figure 11: MTHFR gene.  
(a) MTHFR gene – chromosome 1 (base on http//: www.ivfconnections.com )  (b) MTHFR protein 
(base on http//: www.lovingourguts.com ) 
TPMT polymorphism 
TPMT (located on chromosome 6p22.3) (Figure 12) catalyzes the S-methylation of thiopurine 
drugs, such as 6-MP, 6-TG and AZA, to inactive metabolites (Weinshilboum and Sladek 1980, 
McLeod, Krynetski et al. 1995, Krynetski, Tai et al. 1996). Thiopurines are part of the routine 
treatment for patients with malignant (ALL) and inflammatory diseases (rheumatoid arthritis), 
and are used as immunosuppressant to prevent rejection after organ transplantation. TPMT 
enzyme activity in human tissues is controlled by a spectrum of TPMT genetic polymorphisms 
(Weinshilboum and Sladek 1980, McLeod, Krynetski et al. 1995, Krynetski, Tai et al. 1996, 
Tai, Krynetski et al. 1997). Variations in TPMT activity impact on treatment toxicity and 
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efficacy. Patients with low or undetectable levels of TPMT activity have the highest risk of 
developing severe myelosuppression when treated with standard doses of thiopurines whereas 
patients with very high TPMT activity are more likely to have a reduced clinical response to 
these cytotoxic agents (Evans, Horner et al. 1991, Lennard, Gibson et al. 1993, Lilleyman and 
Lennard 1994). Four common TPMT alleles have been identified in the TPMT gene (i.e., 
TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C) which account for approximately 80% of 
Caucasians with low or intermediate TPMT activity. The TPMT*3A allele is mutated at both 
nucleotides G460A and A719G whereas TPMT*3B and TPMT*3C only have the G460A or 
A719G mutation, respectively (SZUMLANSKI, OTTERNESS et al. 1996, Otterness, 
Szumlanski et al. 1997, Yates, Krynetski et al. 1997).  
The association between low TPMT activity and excessive hematological toxicity is now well 
recognized (McLeod, Lin et al. 1994, McLeod, Krynetski et al. 1995, Otterness, Szumlanski et 
al. 1997). Patients with low or undetectable levels of TPMT activity develop severe 
myelosuppression when treated with “standard” doses of thiopurines, while patients with very 
high TPMT levels are more likely to have a reduced clinical response to these agents (Evans, 
Horner et al. 1991, McLeod, Miller et al. 1993, Lilleyman and Lennard 1994). A 1999 study in 
180 children identified an important role for TPMT genotype on tolerance to 6-MP therapy 
(Relling, Hancock et al. 1999). Two of the patients were TPMT-deficient and tolerated a full 
dose of 6-MP for only 7% of weeks of the planned therapy. Heterozygous and homozygous 
wild type patients tolerated full doses for 65% and 84% of weeks of therapy over 2.5 years of 
treatment, respectively. The percentage of weeks in which 6-MP dosage had to be decreased to 
prevent toxicity was 2%, 16%, and 76% in wild type, heterozygous, and homozygous variant 
individuals respectively (Relling, Hancock et al. 1999). 
Interethnic variability in RBC, TPMT activity has been reported in several populations. RBC 
TPMT was 29% higher in Saami subjects in Northern Norway compared to white subjects 
from the same geographic region (Klemetsdal, Tollefsen et al. 1992). African American 
subjects have 17-33% lower RBC TPMT activity than American white subjects (Jones, Smart 
et al. 1993, Krynetski, Schuetz et al. 1995). The TPMT activity in African and white 
Americans was substantially lower than that reported in 119 Chinese subjects (Lee and Kalow 
1993). 
The frequency and pattern of variant alleles is different among various ethnic populations. For 
example, Southwest Asians (Indian, Pakistani) have a lower frequency of variant TPMT 
alleles, and all variant alleles identified to date are TPMT*3A (Collie-Duguid, Sludden et al. 
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1999). This is in contrast to Kenyans and Ghanaians where the frequency of variant alleles is 
similar to Caucasians but all variant alleles are TPMT*3C (Ameyaw, Collie-Duguid et al. 
1999, McLeod, Pritchard et al. 1999). Conversely, in Caucasian populations TPMT*3A is the 
most common allele, but TPMT*2 and TPMT*3C are also found (Collie-Duguid, Sludden et 
al. 1999). Among African Americans TPMT*3C is most prevalent, but TPMT*2 and 
TPMT*3A are also found (Hon, Fessing et al. 1999). This highlights the genetic admixture in 
the African American population that has been observed by others. It also points to the desire 
to perform genotype analysis in individual patients, in order to optimize the safety and efficacy 
of specific medications. 
The prevalence of TPMT*3A mutation ranges from 0.9 to 5.7% in Caucasians and 0% in 
Asians (Ameyaw, Collie-Duguid et al. 1999, Zhou 2006, Tumer, Ulusoy et al. 2007) whereas 
the prevalence of TPMT*3C mutation varies between 0.6 to 3% in Asians and 0.3 to 1.6% in 
Caucasians (Spire‐Vayron de la Moureyre, Debuysere et al. 1998, Ameyaw, Collie-Duguid et 
al. 1999, Sasaki, Goto et al. 2006, Zhou 2006).                                      
(               
                    (a)  
    (b)  
Figure 12: TPMT gene. (a) TPMT gene – chromosome 6 (base on http//: www.ghr.nlm.nih.gov ) (b) 
TPMT protein (base on http//: www.depts.washington.edu ) 
TS polymorphism 
TS (located on chromosome 18p11.32) (Figure 13) catalyzes the conversion of dUMP to dTMP 
which is required for DNA synthesis and repair (Radparvar, Houghton et al. 1988). The 
inhibition of this enzyme leads to deoxythymidine triphosphate (dTTP) depletion, chromosome 
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break and cell death (Welsh, Titley et al. 2000). A 28-bp polymorphic tandem repeat sequence 
in the 5' untranslated enhancer region of the human TS gene has been shown to influence TS 
expression. A polymorphism in the TSER has been shown to contain either two (TSER*2) or 
three (TSER*3) 28 bp tandem repeats. Compared to a double tandem repeat (TSER*2), the 
presence of a triple tandem repeat (TSER*3) increases TS expression in vitro, and is associated 
with higher in vivo tumor TS activity (Marsh 2005). Whereas homozygous TSER*3 correlates 
with increased TYMS expression in childhood ALL (Horie, Aiba et al. 1995), this variant may 
also be associated with MTX resistance and with a higher risk of relapse (Horie, Aiba et al. 
1995, Giovannetti, Ugrasena et al. 2008). Accordingly, determining the TS genotype may help 
predict the patient response to cytotoxic treatment (Krajinovic, Costea et al. 2002). The 
prevalence of homozygous TSER*3 lies between 28 to 30% and 50 to 77% in Caucasian and 
Asian ALL children, respectively (Marsh, Ameyaw et al. 2000, de Jonge, Hooijberg et al. 
2005, Giovannetti, Ugrasena et al. 2008). 
 
(a)  
 
                               (b)  
Figure 13: TS gene. (a) TS gene – chromosome 18 (base on en.wikipedia.org) (b) TS protein (base on 
http://www.ott.nih.gov )  
  
47 
 
 
 
 
 
 
 
2. Aims of study   
48 
 
2. Aims of study 
General Aim: 
Objectives of our study are to clarify roles of pharmacogenetics affecting transport and 
metabolism of chemotherapeutic drugs in the treatment of childhood ALL and will focus 
particularly on MTX. Thereby it might be possible to give more individualized treatment to 
improve therapeutic and reduce toxic effects. This study is based on the FRALLE 2000 
protocol with extensive use of HD-MTX therapy. The overall aim is to find out new possible 
predictive factors in childhood ALL which are helpful to assess the value of established 
predictive factors for adverse effects of MTX and 6-MP in treatment.  
Specific Aims: 
1. To analyse therapeutic effects of protocol FRALLE 2000 on two groups of childhood ALL, 
Asian patients in Vietnam and Caucasian patients in Belgium: 
 
1.1. To compare the characteristics of patients and the application of protocol FRALLE 
2000 between these two groups. 
 
1.2. To compare the side effects of  HD-MTX and 6-MP, two main drugs in protocole 
FRALLE 2000, between these two group. 
 
1.3. To analyse RFS of these two groups: 
1.3.1. To compare RFS between these two groups. 
1.3.2. To analyze  which group’s characteristics have an impact on the RFS.  
 
1.4. To analyse the impact of relapse between these two group. 
 
2. To analyse the roles of 7 important polymorphisms (CCND1 G870A, GGH C452T, 
MTHFR A1298C, MTHFR C677T, TS, and ITPA C94A, TPMT) influencing the transport 
and metabolism of HD-MTX and 6-MP. 
 
2.1. To identify the frequency of those 7 polymorphisms in both series.  
 
2.2. To analyse the correlations between 7 polymorphisms and RFS as well as ALL risk. 
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3. Materials and Methods 
Patients and treatment 
Caucasian and Vietnamese series of patients:  
The Caucasian series included 94 ALL patients diagnosed under the age of 21 (mean age 6.66 
± 4.57 years with a median of 5.0 years, range: 1-20 years) between 2000 and 2011, and 
followed at the Cliniques Universitaires Saint-Luc (Université catholique de Louvain (UCL)), 
Brussels, Belgium. The Vietnamese series included 141 ALL patients diagnosed under the age 
of 16 (mean age 5.57 ± 3.52 years  with a median of 5.0 years, range: 1-15 years) between 
2005 and 2011, and followed at the Blood Transfusion and Hematology Hospital, University of 
Medicine Pham Ngoc Thach (UPNT) at Ho Chi Minh city, Vietnam.  In both series, the 
patients were treated according to the FRALLE 2000 protocol. Only patients with therapy 
compliance were considered for this study. 
Four and 25 patients were excluded from the Caucasian and Vietnamese series, respectively 
either because of a very young age (less than 1-year-old) or the presence of the Philadelphia 
chromosome. In these conditions, the treatment protocol differed between Belgium and 
Vietnam. Furthermore, the treatment protocol also differed between Belgium and Vietnam for 
relapsing patients. Accordingly, the current study compared the RFS between both series of 
ALL children. 
Acute Lymphoblastic Leukemia features in both series 
The diagnosis of ALL was based on BM and blood morphology according to the FAB 
classification, immunology, cytogenetic and molecular biology. Karyotype was performed in 
50% of Vietnamese patients and 100% of Caucasian patients. Regarding cytogenetic studies, 
abnormalities were categorized in good and poor prognostic factors. Good prognostic factors 
include hyperdiploidy with more than 55 chromosomes, presence of t (12; 21), t (1; 19), and 
normal karyotype. Poor prognostic factors include: hypodiploidy with less than 45 
chromosomes, MLL-rearrangement, or t (4; 11). 
Treatment follow-up and dose intensity  
To assess treatment response, BM examination and MRD evaluation were carried out at day 35 
of the induction phase in both groups. CSF was studied at each IT injection. After completion 
of therapy, BM and CSF were examined on a regular basis during 3 years. At the end of this 
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time interval, children were considered to be cured. In contrast, treatment failure was classified 
as isolated CNS relapse, isolated BM relapse, combined BM relapse, and EM relapse. 
As there was no reduction of dose in both series during the induction or consolidation phases, 
dose intensity of MTX and 6-MP were only calculated during the maintenance therapy. Indeed, 
it is worth noting that occurrence of toxicity was not handled the same way in Vietnam and in 
Belgium. In Belgium, the dose was temporarily reduced but drug regimens were only 
exceptionally stopped. In contrast, medications in Vietnam were stopped and resumed later so 
that each patient received ultimately 100% of the total dose required but not during the same 
time period. Accordingly, the occurrence of toxicity gave rise to longer treatment duration in 
Vietnam. The dose intensity was therefore computed for each patient of both series as the ratio 
between the total received dose and the treatment duration.  
Toxicity recorded in the Caucasian and Vietnamese series  
Toxicities of HD-MTX included mucositis, neutropenia, diarrhea, skin rash, liver failure, 
central neurotoxicity, and leukoencephalopathy.  Only grade 3 or 4 were considered. 
Laboratory technique 
 
Figure 14 : Methods of laboratory 
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DNA and RNA isolation 
For each subject, two venous blood samples (7.5 mL) were collected in EDTA tubes. The 
extraction of genomic DNA was performed from peripheral blood lymphocytes using the EZ1 
DNA Blood kit and BioRobot EZ1 (Qiagen, Leusden, The Netherlands), according to the 
manufacturer’s protocol (Figure 14). 
Total RNA was isolated from whole blood over a Ficoll Hypaque and extracted with TRIzol® 
reagent (Invitrogen Life Sciences, Merelbeke, Belgium) according to the manufacturer’s 
protocol (Figure 14). 
Concentrations of extracted DNA and RNA were measured both using the NanoDrop® ND-
1000 Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and were stored at 
-20°C and -80°C until use, respectively. 
Pyrosequencing 
Identification of polymorphisms of the following genes was carried out: CCND1- (G870A), 
GGH- (C452T) and MTHFR- (A1298C) genes. Pyrosequencing was performed on a PSQ 96 
MA (Qiagen, Vento, Belgium, Nertherlands). Primers used in polymerase chain reaction (PCR) 
and pyrosequencing (QIAGENE GmbH, Hilden, Germany), and size of corresponding 
amplicons are given in Table 2. The PCR reaction mixture was as follows: 5 µL buffer (10 mM 
Tris hydrochloride, and 50 mM potassium hydrochloride, pH 8.3), 3 mM MgCl2, 1U Taq Gold 
polymerase, 200 µM of each dNTP, 10 pmol of each primer and 5 µL (~150-200 ng) of 
genomic DNA in a final volume of 50 µL. The cycling conditions were 95°C for 5 minutes, 
followed by 40 cycles at 95°C for 40 seconds, 60°C for 40 seconds, and 72°C for 80 seconds, 
with a final extension step at 72°C for 7 minutes. 
For each target gene, a sequencing primer was further hybridized to the PCR product and 
incubated with reagents containing enzymes and substrates. One dNTP was added to the 
reaction mixture at a time and was incorporated into the DNA strand if it was complementary 
to the base in the template strand. The incorporation resulted in a release of pyrophosphate that 
was converted to ATP, which in turn drived conversion of the substrate luciferin to 
oxyluciferin, therefore generating light corresponding to a peak. 
 
                     
. 
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Figure 15: Pyrosequencing. (a) Pyrosequencing technical (jonhanneswilbertz.com)    (b) Result of our study: GGH C452T (C/T) and CCND1 G870A (T/T) 
                 
 
Table 2: Target genes and related single nucleotide polymorphisms: primers and probes used in the various pharmacogenetic assays 
Target Gene and related  
polymorphism 
Genbank 
(NCBI) 
Accession 
Location  RS Number 
Forward and reverse primers (5’ – 3’) used  
in polymerase chain reaction 
Target 
size (bp) 
Pyrosequencing primer (1) ,  
Taqman probes (2) 
(5’ – 3’) 
CCND1  
(G870A) 
NG_007375.1 11q13 rs603965 
F: Biot- CAC ACG CTT CCT CTC CAG AGT 
R:  CAT TTC CGT GGC ACT AGG TG 
108 S: GGACATCACCCTCACTTA(1) 
GGH  
(C452T) 
NG_028126.1 
 
8p12.3 rs11545078 
F:  GAG CTT TCA CTG CTG ATT AGT GG 
S:  Bio-TAC TTA CTA ATC CTG CCC AGC AA 
142 S:  ATTAGTGGAGAGTGCTTAT (1) 
MTHFR  
(A1298C) NG_013351.1    
 
1p36.3 
 
rs1801133 
F: GGGAGGAGCTGACCAGTG 
R: Biot-CGCAGCAGCTCCTCCT 
422  S: AGGAGCTGACCAGTGAA-3(1) 
MTHFR  
(C677T) 
rs1801131 
F: AAG CAC TTG AAG GAG AAG GTG TC 
R: CCT CAA AGA AAA GCT GCG TGA 
64 
VIC-ATGAAATCGGCTCCC-MGB(2) 
FAM-ATGAAATCGACTCCCGC-MGB(2) 
TSER 
(2R, 3R, 4R) 
NG_028255.1.  18p11.32 Not applicable 
F: CTG GCG CAC GCT CTC T 
R: FAM-TTG GAT CTG CCC CAG GT 
315 Not applicable 
TPMT 
(G460A and/or A719G )  
NM_000367.2 6p22.3 
rs1800460  
rs1142345 
F:  GGAAGACATATGCTTGTGAGACA 
R:  AAAAACATGTCAGTGTGATTTTATTTT 
818 Not applicable 
ITPA (C94A)  NC_018931.2 20p13 rs1127354 
 
F: Biot- CTGAGTTGGTAAGCTTTAGGAGA 
R: CCAATATTAACTGAACCCTAGAGG 
 
483 GCCACCAAAGTGCAT 
Biot: biotine ; Fam: mutated probe; MGB :  Minor Groove Binding;  NCBI: National Center for Biotechnology Information; VIC: wild type probe 
(b)  
(a) Pyrosequencing technical 
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Taqman real-time PCR assay using MGB probes   
The MTHFR- C677T polymorphism was studied with two Taqman probes added together in 
one polymerase chain reaction (PCR) tube, each consisting of an oligonucleotide with a 
fluorescent reporter dye, a non-fluorescent quencher and an MGB group (Applied 
Biosystems, Foster City, CA, USA). VIC and FAM reporter dyes were used for the WT and 
mutated probes, respectively. A distinct emission wavelength maximum for each probe 
allowed the detection of allele-specific cleavage. PCR primers and MGB probes are detailed 
in Table 2. The reaction was carried out on the ABI PRISM 7900 machine with SDS 2.4.0 
software (Applied Biosystems) in a final volume of 25 µl with 900 nM of forward and reverse 
primers, 200 nM of probes labeled with VIC and FAM, 12.5 µl of TaqMan® 2XUniversal 
Master Mix (Applied Biosystems), and 2.5 µl (~76 – 100 ng) of DNA sample. 
 
(a) TaqMan technical 
(b)  
Figure 16: Taqman real-time PCR assay using MGB probes. 
(a) TaqMan technical (source on medicine.tcd.ie/ Applied Biosystems) 
(b) Result of MTHFR C677T polymorphism with real-time PCR 
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Polymerase chain reaction amplification 
TYMS-TSER polymorphisms (TSER*2 and TSER*3) were analyzed by PCR using: buffer 
1x, 1.5 mM MgCl2, 2U Taq Gold polymerase, 200 µM dNTP, 10 pmol of each primer, 2.5 µL 
DMSO (Dimethylsulfoxyde) and H2O to reach a final volume of 50 µL. The cycling 
conditions were 95°C for 5 min, followed by 35 cycles at 95°C for 40 s, 60°C for 40 s and 
72°C for 1 min 20 s with a final extension step at 72°C for 7 min.  The forward and reverse 
primers used for classic PCR of the TYMS-TSER gene are described in Table 2. DNA 
fragments for TSER*2 and *3 genotypes were run in a 2.5% agarose gel with ethidium 
bromide and visualized on a UV transilluminator. Sequencing analysis was performed in the 
assay validation phase as well as to confirm any unusual genotype (TSER*4). The DNA 
sequence of the purified product was determined on an automated ABI 3130 Genetic 
Analyzer using the BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems).  
  
 
Figure 17: Polymerase chain reaction amplification. (a) PCR methods (b) Result of TSER 
polymorphism: migration on gel agarose 2.5%. 
(a) 
(b) 
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TPMT cDNA amplification 
Total RNA was isolated from venous blood using Trizol reagent (Roche) and retro-
transcribed by SuperscriptTM II RNase H-reverse transcriptase (Invitrogen) according to the 
manufacturers’ instructions. TPMT complementary DNA (cDNA) was amplified by PCR 
using Ampli Taq DNA polymerase (Applied Biosystems) and a pair of primers that anneal to 
sequences within exon 4 and exon 10 of the published sequence of the TPMT cDNA (NCBI: 
accession number BC009596) (Table 2), as previously reported (Dewit, Moreels et al. 2011). 
cDNA sequencing was performed on both strands with the Big Dye® terminator cycle 
sequencing kit (Applied Biosystems), using an automated ABI3130 capillary sequencer. 
Sequences were compared with the wild-type sequence using the SeqScap version 2.0 
software, which identifies variant and sequence matches from an allele library. In addition, 
sequences identify variant and sequence matches from an allele library. 
(a) 
(b) 
Figure 18: TPMT cDNA amplification. 
(a) Sequencing method (b) Result of sequencing 
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Statistical Analysis 
Statistical analysis was performed using R 2.15.0 (http://www.r-project.org).  
Within the Caucasian series, all patients were diagnosed for ALL after the beginning of the 
study in Belgium (2001). In contrast, some patients within the Vietnamese series were 
diagnosed for ALL before the beginning of the study in Vietnam (2009). Time between the 
diagnosis of ALL and inclusion into the series was introduced in the modelling as a left-
truncated time in all time-to-event analyses in order to avoid overestimation of post-
diagnostic survival probabilities and likely underestimation of hazard ratios in the Cox 
regression models. 
Considering that Vietnamese families confronted with a relapsing child can rarely afford 
further drug therapy because of the ﬁnancial burden of leukemia care, this study was not 
pursued after the ﬁrst relapse. The RFS time was computed for each patient as the time from 
diagnosis of disease until ﬁrst relapse or death. 
Study I 
The Caucasian and the Vietnamese clinical series were compared for clinical and biological 
variables using the chi-square test for discrete variables and the Student t test for continuous 
variables. RFS was estimated using the Kaplan-Meier product limit method. Curves were 
compared using the log-rank test. Multivariate Cox regression models were utilized for 
modeling the relationship between factors and RFS in the Vietnamese series and the white 
series and in the pooled series.  
Regression models were adjusted for nationality, sex, age at diagnosis, WBC initial count, 
FAB classiﬁcation, abnormal cytogenetics, immunophenotype, and corticosensitivity at day 8. 
Study II 
A multilocus genetic risk score (MGRS) was computed for each patient by summing the 
number of risk genotypes among the seven tested polymorphisms. Survival free of relapse 
curves were compared between low (≤3) and high (≥4) MGRS using the log-rank test. The 
effect of the MGRS was adjusted for clinical variables including race, age at diagnosis, WBC  
initial count, abnormal cytogenetics, corticosensitivity at day 8 (D8) using a multivariate Cox 
proportional hazards regression model.  
All statistical analyses were adjusted for multiple testing using Bonferroni correction, with 
the exception of regression analyses as recommended.   
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STUDY 1: Comparison of Long-term Outcome between Caucasian and 
Vietnamese Children Treated for Acute Lymphoblastic Leukemia 
According to the FRALLE 2000 Protocol. 
Aims of Study: To analyse therapeutic effects of protocol FRALLE 2000 on two different 
ethnic groups, we compared the clinical and biological parameters as well as the respective 
RFS of 2 series of Asian patients in Vietnam (n=141) and Caucasian patients in Belgium 
(n=94) treated according to the same protocol.  
Study Introduction 
The strong correlation of higher incidence of common ALL in early childhood with higher 
levels of socioeconomic development suggests that environmental factors linked to wealth 
contribute significantly to its etiology (Viana, Fernandes et al. 2001, Stiller 2004, Kroll, 
Stiller et al. 2012, Lightfoot, Johnston et al. 2012). The survival of children with ALL is 
lower in developing than in developed countries (Redaniel, Laudico et al. 2010). Indeed, the 
cure rate of childhood ALL is about 80% in resource-rich countries (Schrappe, Reiter et al. 
2000, Pui and Evans 2006), whereas it remains as low as 40% to 50% in developing countries 
owing to the limited wealth resources and weak primary health care delivery system 
(Howard, Pedrosa et al. 2004, Gao, Lu et al. 2006).  
Moreover, relapse related and treatment-related toxicity with fatal outcome also contribute to 
a decrease in the survival rate (Metzger, Howard et al. 2003, Mostert, Sitaresmi et al. 2006, 
Nguyen, Devidas et al. 2008). However, socioeconomic factors are not the only causal 
factors. A study from the US National Cancer Institute’s Surveillance, Epidemiology and End 
Results (SEER) program from 1998 to 2008 showed that a poorer prognosis was observed in 
East Asians, specially Vietnamese and Filipinos, living in the United States, compared with 
non-Hispanic whites (Goggins and Lo 2012). This finding was interesting in that Asian ethnic 
groups do not seem to be socioeconomically disadvantaged (Goggins and Wong 2009, 
Goggins and Lo 2012). 
In the current study, we compared the clinical and biological parameters as well as the 
respective RFS of 2 series of white and Vietnamese children with ALL treated according to 
the same FRALLE 2000 protocol. Considering that MTX is one of the most active agents for 
the treatment of ALL and is, as such, an essential component of most modern ALL frontline 
treatments worldwide, attention was also paid to the dose intensity of MTX and 6-MP and the 
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occurrence of adverse reactions. HD-MTX offers the advantage of targeting EM leukemia by 
producing cytotoxic concentrations in sanctuary sites where low-dose MTX does not readily 
distribute (eg, testes and CSF) (Barredo, Devidas et al. 2006, von Stackelberg, Hartmann et 
al. 2008). 
Study Results and Discussion 
The similarities and differences between two groups, Asian patients in Vietnam 
and Caucasian patients in Belgium, about the characteristics of patients and the 
application of protocol FRALLE 2000: 
Clinical and biological data of both Caucasian and Vietnamese series were compared. There 
was no statistically significant difference in terms of sex, age at diagnosis, initial WBC count, 
CSF involvement at diagnosis, abnormal cytogenetic, and corticosensitivity at day 8. In 
contrast, Caucasian and Vietnamese clinical series differed significantly in terms of cytology 
(more L2-ALL in Vietnamese children (P<0.001)), flow cytometry (more T-ALL in 
Caucasian children (P=0.004)), a higher mean dose intensity of MTX and 6-MP, and more 
frequent grade 3 or 4 adverse reactions in Vietnamese children (P<0.001) (Table 3).  
The distribution of the dose intensity of MTX and 6-MP, relative to the protocol 
recommendations, between both groups was significantly different (Figure 19) . The mean 
relative dose intensity was 0.88 in Belgium and was 0.94 in Vietnam. The number of patients 
who received a dose-intensity below 0.8 was much higher in Belgium. The difference is 
highly significant, also due to the high number of patients studied.  
 
Figure 19: Dose intensity distribution of  6-MP (or MTX) between Vietnamese and Caucasian patients 
The number of patients who received a dose-intensity below 0.8 was much higher in 
Belgium. The difference is highly significant, also due to the high number of patients studied.  
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Table 3: Clinical and Biological Characteristics of Patients. 
Variables 
Caucasian 
(n=94) 
Vietnamese 
(n=141) 
χ2 value p value 
Sex – no. (%) 
    Boys 
    Girls 
 
65 (69.1) 
29 (30.9) 
 
84 (59.6) 
57 (40.4) 
 
 
1.835 
 
 
0.176 
Age at diagnosis – yr. 
    Mean 
    Median 
    Range 
    ≤ 10 years – no. (%) 
    > 10 years – no. (%)    
    Missing 
 
6.67 
5.0 
1-20 
72 (76.6) 
22 (23.4) 
0 
 
5.57 
5.0 
1-15 
113 (80.1) 
18 (12.8) 
10 
 
 
 
 
 
0.09 
WBC initial count– no. (%)     
    <50.000/mm³ 
    ≥50.000/mm³ 
    Missing 
73 (77.7) 
21 (22.3) 
0 
103 (73.1) 
28 (19.9) 
10 
<0.001 0.99 
CSF involvement – no. (%) 
    No 
    Yes 
 
3 (3.2) 
91 (96.8) 
 
3 (2.1) 
138 (97.9) 
 
 
0.257 
 
 
0.613 
FAB classification – no. (%) 
    Type L1 
    Type L2 and other type 
    Missing 
 
51 (54.3) 
43 (45.7) 
0 
 
18 (12.8) 
113 (80.1) 
10 
 
 
40.367 
 
 
< 0.001 
Abnormal cytogenetics (*) –     no. (%) 
    Good prognosis 
    Poor prognosis 
    Missing 
 
88 (93.6) 
6 (6.4) 
0 
 
127 (90.1) 
4 (2.8) 
10 
 
 
0.752 
 
 
0.386 
Flow cytometry – no. (%) 
    B precursor 
    T precursor 
    Missing 
 
75 (79.8) 
19 (20.2) 
0 
 
122 (86.5) 
8 (5.7) 
11 
 
 
8.89 
 
 
0.004 
Corticosensitivity at D8 – no. (%) 
    Sensitive 
    Resistant 
    Missing 
 
85 (90.4) 
9 (9.6) 
0 
 
111 (78.7) 
20 (14.2) 
10 
 
 
1.113 
 
 
0.291 
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Variables 
Caucasian 
(n=94) 
Vietnamese 
(n=141) 
χ2 value p value 
Dose intensity of MTX or 6-MP (%) 
    Min 
    Max 
    Mean 
    Median 
 
52 
100 
88 
94 
 
43 
100 
94 
95 
 
 
 
9.529 
 
 
 
<0.001 
ADR of HD-MTX (grade 3 or 4)–no. (%) 
    No 
    Yes 
    Missing 
 
88 (93.6) 
6 (6.4) 
0 
 
89 (63.1) 
42 (29.8) 
10 
 
 
19.99 
 
 
< 0.001 
(*) Abnormal cytogenetics: good prognostic factors include hyperdiploidy with more than 55 chromosomes, 
presence of t(1;19) or t(12;21), and normal karyotype. Poor prognostic factors include: hypodiploidy with fewer 
than 45 chromosomes, MLL-rearrangement and presence of t (4; 11). 
      Bold values emphasise significant results. 
      ADR indicates adverse drug reaction; CSF: cerebrospinal fluid; FAB: French-American-British 
classification; HD-MTX: high-dose methotrexate; MTX: methotrexate; 6-MP: 6-mercaptopurine. 
Impact factors on Relapse Free Survival (RFS) of these two groups: 
Relapse Free Survival was significantly higher in Caucasian: 
RFS at 18 months and 5 years from diagnosis was 95.7% (95% confidence interval (CI), 
91.7%-99.9%) and 83.8% (95% CI, 76.3%-92.0%) for Caucasian children, respectively, 
versus 70.4% (95% CI, 60.4%-82.0%) and 47.8% (95% CI, 35.6%-64.2%) for Vietnamese 
children, respectively (Fig. 21). 
 
Figure 20: Relapse-free survival by ethnic origin. 
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Cox proportional hazards regression models were built for each clinical series (Caucasian, n=94; 
Vietnamese, n=141) and in the pooled series (n=235). Adjusted HRs is shown in Table 4. 
Table 4: Clinical and Biological Characteristics of ALL Patients: Hazard Ratios from 
Multivariate Cox Regression Models for RFS. 
 
 
Caucasian Patients  
(n=94) 
Adjusted HR 
Vietnamese Patients  
(n=141) 
Adjusted HR 
Total Patients  
(n=235) 
Adjusted HR 
P 
Nationality 
Caucasian 
   Vietnamese 
 
 
4.48 (2.16 - 9.3) 
 
< 0.001 
Sex 
          Boys 
          Girls 
1.51 (0.49 - 4.66) 1.13 (0.55 - 2.33) 1.16 (0.64 - 2.09) 0.62 
Age at diagnosis (yrs) 
         < 10 years 
         ≥ 10 years 
 
 
1.19 (0.36 - 4.0) 
 
 
1.33 (0.49 - 3.66) 
 
 
1.22 (0.59 - 2.52) 
 
 
0.59 
WBC initial count 
          <50.000/mm3 
          ≥50.000/mm3 
 
 
2.48 (0.66 - 9.33) 
 
 
1.45 (0.58 - 3.63) 
 
 
1.69 (0.83 - 3.46) 
 
 
0.15 
FAB classification 
     Type L1 
     Type L2 and  
         other type 
 
1.02 (0.36 - 2.94) 
 
0.64 (0.23 - 1.8) 
 
0.82 (0.39 - 1.71) 
 
0.59 
Abnormal Cytogenetic 
         Good prognosis 
         Poor prognosis 
 
 
2.07 (0.3 - 14.19) 
 
 
3.69 (0.92 - 14.88) 
 
 
3.26 (1.14 - 9.31) 
 
 
0.03 
Flow Cytometry 
         B precursor 
         T precursor 
 
 
1.39 (0.35 - 5.58) 
 
 
0.61 (0.1 - 3.71) 
 
 
1.13 (0.46 - 2.79) 
 
 
0.79 
Corticosensitivity at D8 
         Sensitive 
         Resistant 
 
 
1.88 (0.4 - 8.8) 
 
 
1.52 (0.58 - 3.99) 
 
 
1.54 (0.7 - 3.41) 
 
 
0.28 
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Ethnic origin was found to be significant in Vietnamese children compared with Caucasian 
children (adjusted HR, 4.48; P<0.001). Vietnamese and Caucasian children with poor 
prognostic cytogenetic abnormalities had a higher risk of relapse with an HR of 3.69 and 
2.07, respectively. An HR of pooled series was 3.26 (P=0.03). In Vietnam, BM and CSF 
relapses occurred very early, mostly within 18 months after diagnosis (Fig. 22). Compared 
with the Caucasian series, Vietnamese children had a higher risk of CSF relapse (HR=5.06; 
P=0.015) and BM relapse (HR=2.86; P=0.023). No significant difference was found between 
Caucasian and Vietnamese children in terms of EM relapse and combined BM and EM 
relapse. 
 
Figure 21: Type of Relapse in white and Vietnamese series.  
BM: bone marrow; CSF: cerebrospinal fluid; EM: extramedullary. 
In this comparative study of childhood ALL between Caucasian patients living in Belgium 
and Vietnamese patients living in Vietnam, the RFS was poorer in Vietnamese children 
(HR=4.48, P<0.001). Despite being treated with the same first-line protocol, Vietnamese 
children relapsed much earlier in BM and CSF than Caucasian children. The RFS at 18 
months and at 5 years from diagnosis was significantly higher in Caucasian than in 
Vietnamese children. 
Survival of children with ALL in developing countries is lower than in developed countries: 
Survival of children with ALL in developing countries is reported to be lower than in 
developed countries. The most common causes of treatment failure reported are as follows: 
treatment discontinuation, lack of antibiotic prophylaxis, poor social status, and insufficient 
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high-quality health care system (Viana, Fernandes et al. 2001, Ribeiro and Pui 2005, Gao, Lu 
et al. 2006, Tang, Xu et al. 2008, Redaniel, Laudico et al. 2010, Wiemels 2012). 
In Vietnam, a developing country, the costs for diagnostic and follow-up tests and for drugs 
in children under the age of 6 are covered at 100% by health insurance, whereas figures drop 
to 80% for children older than 6 years. Families hospitalizing a child have to pay for hospital 
beds (including for the person accompanying the patient) and for meals. Therefore, only 
patients with sufficient financial resources (ie, middle and upper class) were included and 
treated with FRALLE 2000 protocol. Patients who discontinued the treatment were excluded 
from the study. Supportive therapy was similar in both countries except for the additional use 
of acyclovir in Belgium. However, Vietnamese families confronted with a relapsing child 
could rarely afford further drug therapy because of the financial burden of leukemia care. 
That is the reason why we did not compare the outcome after the first relapse. 
Available data were assessed to approach the reasons for such differences. Both series were 
comparable as far as age, sex, initial WBC count, and abnormal cytogenetic at diagnosis were 
concerned. 
Impact factors on RFS in the application of protocol FRALLE 2000 
Corticosensitivity at day 8 of treatment was similar in both series. L2-ALL was more frequent 
in Vietnamese children (P<0.01), whereas T-ALL was less frequent in the same series 
(P<0.01). T-ALL was present in 5.6% of the Vietnamese patients. This is similar to the 5.8% 
reported in the SEER study (Goggins and Lo 2012). The reason for such differences has not 
been determined but should not explain the worse prognosis observed in Vietnamese children. 
In contrast, T-ALL is known to have a worse prognosis. The SEER study reports a survival 
probability in the United States of 66% in East Asians with T-ALL as compared with 80% for 
B-ALL. As expected, poor prognostic cytogenetic aberrations had a negative impact on both 
groups. In that respect, RFS in Vietnamese children with poor cytogenetic abnormalities had 
an HR value nearly twice that found in Caucasian children (3.69 vs. 2.07, respectively). It 
implies a much more marked RFS difference in Vietnamese children with poor-risk and 
good-risk cytogenetic than observed in their Caucasian counterparts. Considering the worse 
RFS in Vietnamese children, the same observation applies with a strikingly higher difference 
between Vietnamese and Caucasian children with poor prognostic abnormalities compared 
with the difference observed in their respective counterparts with good prognostic 
abnormalities. 
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With regard to the first IT therapy, there was a substantial difference between both series. In 
the Belgium series, the first lumbar puncture was combined with the first IT injection. In the 
Vietnamese series, the first IT injection was delayed for a few days after diagnosis when the 
WBC count was high or when the lumbar puncture appeared to be traumatic. Both situations 
could have a negative impact on RFS as an intervening CSF contamination by leukemic cells 
may then not be ruled out (Rech, de Carvalho et al. 2005). Furthermore, CNS involvement at 
diagnosis may be underestimated as the first lumbar puncture is performed when the WBC 
count is already reduced by 50%. 
Side effects of high dose Methotrexate and Mercaptopurine, two main drugs in 
protocole FRALLE 2000, between two groups: 
A higher incidence of toxic events was observed in children aged 10 years and over at 
diagnosis, as well as in children being corticoresistant at day 8 (data not shown). In both 
situations, a dose-intensified treatment was administered inducing more toxicity. Even though 
HD-MTX administration was similar in both series, the incidence of HD-MTX-related grade 
3 and 4 adverse events was significantly higher in Vietnamese children (P<0.01). One of the 
reasons might be the lack of pharmacokinetic monitoring of HD-MTX in Vietnamese 
children, which precludes any dosage adjustment, hence increasing the risk of MTX toxicity. 
An additional contribution of socioeconomic factors and/or variations in pharmacogenetic 
polymorphisms in Vietnamese patients cannot be ruled out, and this may also affect the 
metabolism of the drug and the outcome of Vietnamese children (Bhatia 2004, Cheok and 
Evans 2006, Kager and Evans 2006, Przekop, Tulgan et al. 2006, Goggins and Wong 2009, 
Goggins and Lo 2012). 
Except for the first IT injection and the assessment of HD-MTX clearance, induction and 
consolidation phases were strictly comparable, whereas maintenance therapy differed in both 
series in terms of management of drug toxicity. In the latter case, Caucasian children received 
a reduced dose of 6-MP and MTX and discontinued the treatment after 18 or 24 months 
according to the protocol. In contrast, the Vietnamese children interrupted treatment in case 
of toxicity but resumed it later. Accordingly and compared with Caucasians, each Vietnamese 
patient received the same total dose of each drug but over a longer period of time, which 
ultimately resulted in a significantly higher dose intensity. In that respect, giving 6-MP every 
week has been reported to improve survival. The drug efficacy and survival benefit of 6-MP 
indeed appear associated with chronic systemic exposure to active metabolites of this agent 
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(Koren, Ferrazini et al. 1990, Relling, Hancock et al. 1999). It is therefore recommended to 
reduce the dose according to the WBC count rather than interrupting therapy, irrespective of 
the potential contribution of pharmacogenetics in the metabolism of 6-MP. 
Study Conclusion 
In this study, Vietnamese children with ALL have a worse prognosis than Caucasian children, 
despite receiving the same FRALLE 2000 protocol. It is of course somehow challenging to 
evaluate exactly the impact of socioeconomic factors and health care system differences in 
both series of patients. Nevertheless, only Vietnamese children from families with sufficient 
financial resources were included in this study. The treatment was administered in a single 
university hospital in Vietnam. Lessons to be learned from this study are as follows: firstly, 
the importance to initiate IT therapy as early as possible and to minimize the risk of traumatic 
lumbar puncture; secondly, to point out the need for a pharmacokinetic monitoring of HD-
MTX with dosage adjustment to reduce the MTX-related toxicity; thirdly, to consider dose 
reduction during maintenance therapy rather than treatment interruption as is currently being 
done in Vietnam. There is no doubt whatsoever that increasing government spending on 
health, intensifying the medical training, and improving the disease management by educating 
the parents are concrete measures that are worth being taken into consideration in Vietnam. 
Whether genetic differences in the metabolism and bioavailability of drugs used in the 
treatment of ALL (Cheok and Evans 2006, Kager and Evans 2006), especially MTX and 6-
MP, might also affect the prognosis of ALL in Vietnamese children remains to be 
determined. This justifies further evaluation and comparison of both series of patients. 
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STUDY 2: Comparative pharmacogenetic analysis of risk 
polymorphisms in Caucasian and Vietnamese children with Acute 
Lymphoblastic Leukemia: prediction of therapeutic outcome? 
Aims of Study: Aside from predisposing to ALL, polymorphisms could also be 
associated with poor outcome. Indeed, genetic variations involved in drug metabolism could, 
at least partially, be responsible for heterogeneous responses to standardized leukemia 
treatments, hence requiring more personalized therapy. The aims of this study were to (a) to 
determine the prevalence of seven common genetic polymorphisms including those that affect 
the folate and/or thiopurine metabolic pathways, i.e. CCND1 (CCND1-G870A), GGH-
C452T, MTHFR-C677T and MTHFR-A1298C, TYMS-TSER, TPMT*3A and TPMT*3C 
and ITPA-C94A, in Caucasian (n = 94, age < 20) and Vietnamese (n = 141, age < 16 years) 
childhood ALL and (b) to assess the impact of a MGRS on RFS. 
Study Introduction 
Although current treatment protocols can cure approximately 80% of paediatric ALL patients, 
a number of children will relapse (Pui, Robison et al. 2008), with a relapse rate shown to vary 
within a group of patients with similar risk even though their leukemia blasts carry the same 
characteristics. Besides tumour and patient related factors, inter-individual variations in 
treatment responses and toxicity could also be attributable to genetic polymorphisms 
influencing drug disposition and treatment intensity.  
While multiple drugs are used to treat children with ALL, mounting evidence indicates that 
gene polymorphisms may alter therapy responses, as they participate in folate and 6-MP/AZA 
metabolism, steroid response, drug transport and detoxification (Kager and Evans 2006). 
Polymorphisms in genes interacting with folate metabolism and MTX activity such as the 
MTHFR and the promoter enhancer region of TS (TYMS-TSER), or intervening in the 6-MP 
metabolic pathway such as TPMT and ITPA could explain at least part of the inconsistent 
clinical outcome in children with ALL receiving similar treatments (Aplenc, Thompson et al. 
2005, Rocha, Cheng et al. 2005, Stanulla, Schaeffeler et al. 2005). 
However, data regarding the Caucasian and Vietnamese allelic distribution of polymorphic 
variants involved in MTX metabolism in children with ALL are scarce. Polymorphisms 
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within MTHFR, TS-TSER, TPMP and ITPA, as well as CCND1, GGH genes were assessed 
in this study. 
Study Results and Discussion 
Distribution of genotypes of folate and thiopurine associated polymorphisms in 
Caucasian and Vietnamese children with ALL. 
The distribution of each genotype studied in 94 Caucasian and 141 Vietnamese children with 
ALL is listed in Table 5. 
Table 5: Genotype frequencies of folate and thiopurine pathways associated polymorphisms in 
Caucasian and Vietnamese children with ALL. 
Polymorphic loci Genotype 
Protective 
vs                               
Risk 
Caucasian 
(N=94)
n (%) 
Vietnamese 
(N=141) 
n* (%) 
Raw 
P value 
£ 
Adjusted 
P value ¥ 
CCND1 G870A     0.24 1.00 
 G/G 
G/A 
A/A 
P 
P 
R 
28 (29.8) 
45 (47.9) 
21 (22.3) 
22 (18.6) 
60 (50.9) 
36 (30.5) 
 
 
 
GGH C452T     0.13 0.97 
 C/C 
C/T 
P 
R 
74 (78.7) 
20 (21.3) 
103 (87.3)
 
15 (12.7) 
 
 
 
MTHFR C677T     0.001 0.008 
 C/C P 42 (44.7) 80 (67.8)   
 
 
C/T 
T/T 
R 
R 
43 (45.7) 
9 (9.6) 
36 (30.5) 
2 (1.7) 
 
 
 
MTHFR A1298C     0.153 1.00 
 A/A P 54 (57.4) 55 (46.6)   
 
 
A/C 
C/C 
R 
R 
31 (33) 
9 (9.6) 
54 (45.8) 
9 (7.6) 
 
 
 
TS(TSER)     < 0.001 <0.001 
 *2R/*2R 
*2R/*3R 
P 
P 
20 (21.3) 
41 (43.6) 
3 (2.5) 
35 (29.7) 
  
 
 
*3R/*3R 
*3R/*4R 
R 
R 
33 (35.1) 
0 
79 (67.0) 
1 (0.8) 
  
TPMT(*3A and *3C)     0.31 1.00 
 No mutation P 90 (95.7) 116 (91.3)   
 Mutation 
TPMT*3A 
TPMT*3C 
R 4 (4.3) 
4 (4.3) 
0 
11 (8.7) 
0 
11(8.7) 
  
ITPA A94C     0.003 0.02 
 A/A 
A/C 
C/C 
P 
P 
R 
1 (1.1) 
13 (14.0) 
79 (84.9) 
4 (3.4) 
36 (30.5) 
78 (66.1) 
  
* Sum of n not equals to 141 because of missing data. £Chi-square test to compare reference with associated 
genotype between Caucasian and Vietnamese. ¥Bonferroni adjusted P values for multiple (n=7) testing. 
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The prevalence of CCND1-A870G, GGH-C452T, MTHFRA1298C and TPMT 
polymorphisms between Caucasian and Vietnamese series was not statistically different. 
Although TMPT*3A and TMPT*3C were detected in the Caucasian and Vietnamese series, 
respectively, their frequency was very low. Accordingly, they were pooled together within the 
TPMT group to allow the statistical analysis. 
The prevalence of MTHFR-677TT genotype was significantly higher in the Caucasian (9.6%) 
than in the Vietnamese (1.7%) series (P = 0.008). Conversely, the prevalence of TYMS-
TSER*3R/3R and ITPA-94AC/AA genotypes were significantly higher (P < 0.001 and P = 
0.02, respectively) in Vietnamese (67.0% and 33.9%, respectively) than in Caucasian (35.1% 
and 15.1%, respectively) children with ALL.  
This study showed differences between Caucasian and Vietnamese children with ALL in the 
frequency distribution of MTHFR-C677T, TYMS-TSER and ITPA-C94A polymorphisms. 
Indeed, Vietnamese children had a much higher proportion of TYMS-TSER*3R/3R and of 
ITPA- 94AC/AA genotypes, whereas the prevalence of the MTHFR-677TT genotype was 
very low. No significant difference was found between both series in the frequency 
distribution of CCND1-G870A, GGH-C452T, MTHFR-A1298C and TPMT polymorphisms. 
However TPMT*3A (G460A and A719G) was only found in Caucasian children while 
TPMT*3C (A719G) was only found in Vietnamese children. TPMT*3B (G460A) was found 
neither in Caucasian nor in Vietnamese children.  
Vietnamese children had a two-fold higher prevalence of TSER*3R/3R than Caucasian 
children. These results are in line with data from Dutch (de Jonge, Hooijberg et al. 2005) and 
Indonesian children with and without leukemia (Giovannetti, Ugrasena et al. 2008). It is of 
note that a very rare TSER*3R/4R genotype was identified in a single case from the 
Vietnamese clinical series (one out of 141 children) and was associated with a poor short term 
outcome after chemotherapy. The prevalence of MTHFR-677TT genotype in Caucasian and 
Vietnamese ALL children was 9.6% and 1.7%, respectively. While not found in Caucasian 
children, TPMT*3C is known to be more prevalent among Vietnamese (∼10%) and Thai 
(11%) than among other Asian patients (i.e. Chinese, Japanese, Indian and Malaysian) where 
prevalence ranges between 0.8% and 3% (Sasaki, Goto et al. 2006, Zhou 2006). While GGH-
452TT genotype was not found in this study, this may well be biased by the moderate sample 
size. It is indeed a rare variant being only infrequently reported in a Japanese population (one 
out of 269) (Hayashi, Fujimaki et al. 2007), in Chinese leukemia children (one in 203) (Chen, 
Wen et al. 2012), but not found in Mexican paediatric patients with ALL (n = 70) (Organista-
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Nava, Gómez-Gómez et al. 2010). The prevalence of ITPA-94AC/AA genotypes in 
Caucasian (15.1%) and Vietnamese (33.9%) children with ALL was in line with previous 
studies (Marsh, Ameyaw et al. 2000, Stocco, Cheok et al. 2009, Farfan, Salas et al. 2014). 
Correlations between 7 polymorphisms and RFS. 
The univariate analyses show that the individual impact of each variant was not statistically 
significant probably due to a limited association with RFS and a small sample size. All P 
values were adjusted for multiple testing with Bonferroni correction because of the number of 
hypothesis tests (n = 21) which were simultaneously conducted. The Bonferroni adjusted P 
value obtained with the TPMT*3A genotype in the Caucasian series was not statistically 
significant and should therefore be confirmed in larger clinical series. 
Whereas the association between TPMT polymorphisms and 6-MP cytotoxicity is widely 
accepted (Lennard, Lilleyman et al. 1990, Krynetski, Tai et al. 1996, Zhou 2006), reports on a 
potential association between TPMT mutations and RFS are extremely scarce. In a hospital-
based cohort study of 172 childhood ALL patients (Lilleyman and Lennard 1994), a 6-TGN 
concentration lower than the median concentration value (i.e. 284 pmol per 8 × 108 
erythrocytes) was associated with a 63% RFS at 5 years whereas RFS was 84% at 5 years in 
patients with the median concentration value (RFS difference 21%; 95% CI = 3, 39%; P = 
0.0018). As the 6-MP metabolic pathway is influenced both by TPMT and ITPA genotypes, 
the effect of ITPA genotyping on RFS was also assessed in this study. 
Regarding ITPA variants, it is worth emphasizing that evidence on their impact in terms of 
toxicity and survival are scarce and often controversial (Adam de Beaumais, Fakhoury et al. 
2011, Kim, Kang et al. 2012), which explains why the impact of ITPA on RFS remains so far 
unknown. ITPA- 94CA/AA genotypes appeared both in the Caucasian and Vietnamese series 
as a protective genotype in this study, whereas the wild-type ITPA-94CC genotype was 
associated with a significantly poorer survival. ITPA-94CC was therefore considered as a risk 
factor in univariate analysis of RFS, as well as in the computation of the MGRS. While the 
pharmacologic explanation of the effect of ITPA-C94A on RFS is so far unclear, it could be 
related to the unfavourable effect on the pool of 6-TGN. 6-TGN is indeed incorporated in 
nucleic acids or with phosphate in 6-TITP, a process that determines the clinical efficacy but 
can be reversed by ITPA (Adam de Beaumais, Fakhoury et al. 2011). 
Regarding the impact of the folate pathway, many but not all studies have reported the 
association of genetic variations in the selected genes with the effect of MTX and relapsed 
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risk. In a cohort study (Krajinovic, Lemieux-Blanchard et al. 2004) and case-control study 
(Aplenc, Thompson et al. 2005) of 201 and 137 paediatric patients with ALL, respectively, 
MTHFR-C677T and MTHFR-A1298C variants were indeed associated with an increased risk 
of relapse. 
In a prospective (Rocha, Cheng et al. 2005) and case-control (Haferlach 2003) study of 247 
and 80 childhood ALL patients, respectively, homozygous TSER*3R/3R variants showed a 
greater risk of haematological relapse related to drug resistance. However, the assessment of 
20 polymorphisms located in 11 genes (i.e. GSTM1, GSTT1, GSTP1, NQO1, MTHFR, 
MTHFD1, SLC19A1, ABCB1, TSER, CRC5 and IL15) in a cohort study of 463 paediatric 
ALL patients failed to demonstrate any association between MTHFR and TSER variants with 
event-free survival (EFS). Conversely, ABCB1 3435TT and CCR5 246GA were found to 
predict lower EFS probability than their 3435CC (HR = 2.496; P = 0.012) and 246GG (HR = 
1.82; P = 0.033) genotype counterparts (Lu, Kham et al. 2011). In a Cox regression model of 
EFS adjusted for clinical variables such as ethnicity, gender, age, lineage, initial WBC and 
cytogenetic subtypes, a significant difference (P = 0.0015) was found only with cytogenetic 
subtypes. This is in agreement with our own findings, i.e., a strong association between 
abnormal cytogenetic (associated with a poor prognosis group), Vietnamese ethnicity and the 
risk of relapse (Hoang, Ambroise et al. 2014). 
Multilocus Genetic Risk Score improve the predictive accuracy of the clinical 
model. 
The MGRS was computed for each patient as the number of risk genotypes. In our study, 
MGRS was based on seven genotypes at multiple single nucleotide polymorphisms. It was 
used to identify the association between genetics and risk of relapse in each patient. For 
example: If MGRS was scored at 3 (or 4), it means that the patient had 3 (or 4) risk of relapse 
polymorphisms (Table 6). Because of the limited number of patients, the original MGRS 
ranging between 0 and 6 were dichotomized in two categories (≤3 and ≥4). Compared with 
children with a low MGRS (≤3), a high MGRS (≥4) significantly increased the risk of relapse 
(univariate HR = 2.06; 95% CI = 1.01, 4.21; log rank P value = 0.042) (Figure 23).   
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Table 6 :  Example of MGRS in patients (R = risk, P = protective) 
Gene CCND1 
G870A 
GGH 
C452T 
MTHFR 
A1298C 
MTHFR 
C677T 
TS TPMT     
(*3A et*3C) 
ITPA 
A94C 
MGRS 
Patient 
1 
R R R P P P P 3 
Patient 
2 
R R R R P P P 4 
 
 
 
 
 
The adjusted HR of MGRS between children with a low (≤3) and high (≥4) MGRS computed 
from the multivariate model integrating race/ethnicity and four clinical variables was 
equivalent (HR = 2.09, 95% CI = 1.06, 4.13, P value = 0.03) to the univariate HR (Table 7). 
Adding MGRS to the model only slightly impacted on the highly significant HR of the single 
race/ethnicity variable. Compared with Caucasian children, the risk of relapse in Vietnamese 
Figure 22: Relapse free survival according to multilocus genetic risk score. 
Compared with those with a low MGRS (≤ 3), ALL children with a high MGRS (≥ 4) presented a 
significantly increased risk of relapse (HR=2.06; 95%CI = 1.01 - 4.21; log- rank P value = 0.042) 
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children was increased by 4.39 (95% CI = 2.28, 8.46, P value <0.001) times, irrespective of 
MGRS. 
Table 7: Multivariate Cox proportional-hazard regression model in the pooled series with and 
without multilocus generic risk score. 
  
Cox PH model without MGRS Cox PH model with MGRS 
  
Hazard ratios 
(95%CI) 
p value 
Hazard ratios 
(95%CI) 
p value 
Race  
        
       Belgian  1    1   
       Vietnamese 4.19 (2.20 – 7.97) <0.001 4.39 (2.28 – 8.46) <0.001 
Age at diagnosis 
        
       <10 years  1    1   
       ≥ 10 years 1.26 (0.60 – 2.65) 0.54 1.37 (0.64 – 2.92) 0.42 
Initial WBC count               
        
       < 50.000/mm³  1    1   
       ≥ 50.000/mm³ 1.82 (0.91 – 3.64) 0.09 1.57 (0.77 – 3.17) 0.21 
Abnormal cytogenetics 
        
       Good prognosis  1    1   
       Poor prognosis 3.66 (1.31 – 10.24) 0.01 3.51 (1.23 – 9.99) 0.02 
Corticosensitive at day 8 
       Sensitive 
 
 1 
   
 1 
  
       Resistant 1.41 (0.66 – 3.00) 0.36 1.38 (0.64 – 2.98) 0.42 
MGRS     
    
            ≤ 3      1    
            ≥ 4     2.09 (1.06 – 4.13) 0.03 
Predictive accuracy of the model was higher with than without MGRS on the whole range of 
tested time points. The predictive accuracy of both Cox regression models slightly decreased 
with longer time points (Figure 24). 
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Figure 23: Predictive accuracy of Cox regression models. AUC of the time-dependent ROC curve 
obtained on the cross-validated predictions of the model with (red) and without (blue) MGRS. 
In the current study, the univariate analysis of RFS showed a significant impact of MGRS and 
multivariate analysis indicated being Vietnamese, having a high MGRS and having abnormal 
cytogenetic significantly increased the risk of relapse. MGRS improved the predictive 
accuracy of the clinical model integrating ethnicity and four relevant clinical variables. The 
MGRS benefit was particularly marked during the first 4 years but tended to decrease with 
longer time points. However, there were a restricted number of polymorphisms and patients 
assessed in both clinical case series. Furthermore, the association between selected 
polymorphisms and adverse drug reaction to MTX and 6-MP was not assessable. 
What special results do we get out from this study? 
TSER*3R/4R 
It is of note that a very rare TSER*3R/4R genotype was identified in a single case from the 
Vietnamese clinical series (one out of 141 children) and was associated with a poor short term 
outcome after chemotherapy. 
ITPA 94AA 
Vietnamese children had a higher prevalence of ITPA 94CA and AA than Caucasian 
children. ITPA 94AA genotype in our series was only present in 4/118 Vietnamese children 
and in 1/93 Caucasian child. It is of note that it is a rare genotype in the literature. The ITPA 
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94AA genotype was reported in the literature in 2/100 children in Korea (Kim, Kang et al. 
2012), 0 /103 in Chile (Farfan, Salas et al. 2014) and 0/200 in Japan (Kudo, Saito et al. 2008). 
Study Conclusion 
Although patients in both series were treated according to the same protocol, there were 
major differences in the therapeutic management (Hoang, Ambroise et al. 2014). Limitations 
concerned the day of first IT therapy and the way MTX toxicity was managed (resulting in a 
higher dose intensity in Vietnamese children), which could explain in part the difference of 
RFS between the series. However, it is of note that significant differences in the prevalence of 
the MTHFR, TYMS-TSER and ITPA polymorphism were also detected, suggesting that 
MGRS may improve the predictive accuracy of the clinical model. To strengthen the current 
observation, the impact of pharmacogenetic determinants affecting the folate and/or 
thiopurine pathway genes on RFS in different ethnic groups deserves further study in a larger 
and more homogeneous clinical series of patients. 
Additional SNPs, such as those previously reported (i.e. ATP-binding cassette subfamily B 
member 1 transporter (ABCB1), chemokine receptor 5 (CCR5)) (Lu, Kham et al. 2011), 
could also be integrated as potential predictive factors when further assessing and evaluating 
the strength of association between well determined pharmacogenotypes and outcome of 
paediatric ALL. 
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5. Conclusion and 
Perspective 
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Conclusions and Perspectives: 
There is very little research and articles in the literature who study childhood ALL in 
Vietnam. Our prospective studies compared Vietnamese (n=141) and Caucasian (n=94) 
children with ALL. Based on our findings, the following conclusions could be made: 
- RFS was significantly worse in Vietnamese patients with HR= 4.48, p<0.01, despite 
receiving the same FRALLE 2000 protocol as Caucasian patients. 
- Vietnamese patients had a higher risk of CSF and BM relapse, which occurred earlier 
than in Caucasian patients. 
- The prevalence of MTHFR 677TT, TSER*3R/3R and ITPA 94AA/AC genotypes 
differed significantly between Vietnamese and Caucasian clinical series. 
- Our pooled data suggest evidences for a role of polymorphisms in the MTX and 
thiopurine pathway and risk of relapse. 
Lessons from this study are as follows:  
Firstly, the importance to initiate IT therapy as early as possible and to minimize the risk of 
traumatic lumbar puncture. 
Secondly, the need of performing a pharmacokinetic monitoring for HD-MTX, with dosage 
adjustment in order to reduce the MTX-related toxicity. 
Thirdly, to consider dose reduction during maintenance therapy rather than treatment 
interruption as is currently being done in Vietnam. 
In order to improve the results and to reduce the high rate of early relapses, we need (1) to 
train our pediatricians to do the first IT injection as soon as possible, with a minimal risk of 
traumatic lumbar puncture, (2) to monitor the pharmacokinetic of HD-MTX in order to adjust 
the dose and to administer the leucovorin at the right dose, at the right time. The choice of 
MTX and leucovorin doses may be regarded as an intricate balance between effect and 
counter-effect and (3) to consider a dose reduction during maintenance therapy rather than 
treatment interruption. Indeed, the drug efficacy and survival benefit of 6-MP appear to be 
associated with chronic systemic exposure to active metabolites of this agent. Even if the 
relative dose intensity is higher in Vietnam due to prolonged administration, the efficacy is 
probably reduced by the regular interruption of the maintenance therapy  
Furthermore, significant differences in the prevalence of the MTHFR, TSER and ITPA 
polymorphism were also detected in our study, suggesting that MGRS may improve the 
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predictive accuracy of the clinical model. The higher MGRS have contributed to relapse of 
childhood ALL in this cohort, but we also have to acknowledge that our statistical power was 
limited by the relatively small number of patients included in this study. 
To strengthen these current observations, further study deserves confirmation on a larger 
cohort of patients. Additional SNPs, such as those previously reported (i.e., ABCB1, CCR5, 
RFC1), could usefully be integrated as potential predictive factors when further assessing and 
evaluating strength of association between pharmacogenotypes and outcome of pediatric 
ALL. A resulting drug dose adjustment, if feasible, will be beneficial to the patients. A 
regular review of the literature on the subject will be of upmost importance to keep up to date 
in this very quickly moving field. 
In conclusion, it will probably be necessary to make choices among all these suggestions. 
Improving every day’s clinical practice is essential. Well-trained pediatric 
hematologists/oncologists play an important role in applying the treatment protocol.  
To join the leaders in the field of ALL, rethinking together the protocol, is also a way to 
better understand all the requirements. This will help to apply them all with more accuracy. 
The inclusion of patients in a protocol rather than just following it, is also very important in 
order to follow accurately the guidelines.  
Furthermore, the local specialists are responsible to identify correctable defects in the health 
care system and to implement cost-effective changes. Support from a private foundation 
could help to improve the health care system, to support patients and families who are in 
need, and to raise money to be able to implement new techniques like genotyping and to do 
further research in this very interesting field.  
 
  
80 
 
REFERENCES 
Adam de Beaumais, T., M. Fakhoury, Y. Medard, S. Azougagh, D. Zhang, K. Yakouben and E. Jacqz‐
Aigrain (2011). "Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia 
maintenance therapy." British journal of clinical pharmacology 71(4): 575-584. 
Ameyaw, M.-M., E. S. Collie-Duguid, R. H. Powrie, D. Ofori-Adjei and H. L. McLeod (1999). 
"Thiopurine methyltransferase alleles in British and Ghanaian populations." Human molecular 
genetics 8(2): 367-370. 
Aplenc, R., J. Thompson, P. Han, M. La, H. Zhao, B. Lange and T. Rebbeck (2005). 
"Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute 
lymphoblastic leukemia." Cancer research 65(6): 2482-2487. 
Baldin, V., J. Lukas, M. Marcote, M. Pagano and G. Draetta (1993). "Cyclin D1 is a nuclear protein 
required for cell cycle progression in G1." Genes & development 7(5): 812-821. 
Banerjee, D., P. Mayer-Kuckuk, G. Capiaux, T. Budak-Alpdogan, R. Gorlick and J. R. Bertino (2002). 
"Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase." 
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1587(2): 164-173. 
Barredo, J., T. Synold, J. Laver, M. Relling, C. Pui, D. Priest and W. Evans (1994). "Differences in 
constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage 
leukemia." Blood 84(2): 564-569. 
Barredo, J. C., M. Devidas, S. J. Lauer, A. Billett, M. Marymont, J. Pullen, B. Camitta, N. Winick, W. 
Carroll and A. K. Ritchey (2006). "Isolated CNS relapse of acute lymphoblastic leukemia treated with 
intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study." 
Journal of clinical oncology 24(19): 3142-3149. 
Belgian-Cancer-Registry (2010). Cancer Incidence in Belgium 2010. 
www.kankerregister.org/.../CancerIncBel2010-ChildrenAdolescents.pdf 
Bertino, J., E. Göker, R. Gorlick, W. Li and D. Banerjee (1996). "Resistance mechanisms to 
methotrexate in tumors." Stem Cells 14(1): 5-9. 
Betticher, D. C., N. Thatcher, H. J. Altermatt, P. Hoban, W. Ryder and J. Heighway (1995). "Alternate 
splicing produces a novel cyclin D1 transcript." Oncogene 11(5): 1005-1011. 
Bhatia, S. (2004). "Influence of race and socioeconomic status on outcome of children treated for 
childhood acute lymphoblastic leukemia." Current opinion in pediatrics 16(1): 9-14. 
Bökkerink, J. P., M. A. Bakker, T. W. Hulscher, R. A. De Abreu and E. D. Schretlen (1988). "Purine 
de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human 
malignant lymphoblasts of different lineages." Biochemical pharmacology 37(12): 2321-2327. 
Brockmöller, J. and M. V. Tzvetkov (2008). "Pharmacogenetics: data, concepts and tools to improve 
drug discovery and drug treatment." European journal of clinical pharmacology 64(2): 133-157. 
81 
 
Buch, S., B. Zhu, A. Gaither Davis, D. Odom, J. M. Siegfried, J. R. Grandis and M. Romkes (2005). 
"Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the 
upper aero‐digestive tract." Molecular carcinogenesis 42(4): 222-228. 
Burke, G., E. Estlin and S. Lowis (1999). "The role of pharmacokinetic and pharmacodynamic studies 
in the planning of protocols for the treatment of childhood cancer." Cancer treatment reviews 25(1): 
13-27. 
Caldon, C. E., R. J. Daly, R. L. Sutherland and E. A. Musgrove (2006). "Cell cycle control in breast 
cancer cells." Journal of cellular biochemistry 97(2): 261-274. 
Chabner, B. A., C. J. Allegra, G. A. Curt, N. J. Clendeninn, J. Baram, S. Koizumi, J. C. Drake and J. 
Jolivet (1985). "Polyglutamation of methotrexate. Is methotrexate a prodrug?" Journal of Clinical 
Investigation 76(3): 907. 
Chen, X., F. Wen, L. Yue and C. Li (2012). "Genetic Polymorphism of γ-Glutamyl Hydrolase in 
Chinese Acute Leukemia Children and Identification of a Novel Double Nonsynonymous Mutation." 
Pediatric Hematology-Oncology 29(4): 303-312. 
Chen, Z.-S., K. Lee, S. Walther, R. B. Raftogianis, M. Kuwano, H. Zeng and G. D. Kruh (2002). 
"Analysis of Methotrexate and Folate Transport by Multidrug Resistance Protein 4 (ABCC4) MRP4 Is 
a Component of the Methotrexate Efflux System." Cancer research 62(11): 3144-3150. 
Cheng, Q., B. Wu, L. Kager, J. C. Panetta, J. Zheng, C.-H. Pui, M. V. Relling and W. E. Evans 
(2004). "A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic 
activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells." 
Pharmacogenetics and Genomics 14(8): 557-567. 
Cheok, M. H. and W. E. Evans (2006). "Acute lymphoblastic leukaemia: a model for the 
pharmacogenomics of cancer therapy." Nature Reviews Cancer 6(2): 117-129. 
Collie-Duguid, E., J. Sludden, T. Li and H. McLeod (1999). "The frequency and distribution of 
thiopurine methyltransferase alleles in Caucasian and Asian populations." Pharmacogenetics and 
Genomics 9(1): 37-42. 
Costea, I., A. Moghrabi and M. Krajinovic (2003). "The influence of cyclin D1 (CCND1) 870A> G 
polymorphism and CCND1-thymidylate synthase (TS) gene–gene interaction on the outcome of 
childhood acute lymphoblastic leukaemia." Pharmacogenetics and Genomics 13(9): 577-580. 
Costea, I., A. Moghrabi, C. Laverdiere, A. Graziani and M. Krajinovic (2006). "Folate cycle gene 
variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia." 
haematologica 91(8): 1113-1116. 
Coustan-Smith, E., J. Sancho, M. L. Hancock, J. M. Boyett, F. G. Behm, S. C. Raimondi, J. T. 
Sandlund, G. K. Rivera, J. E. Rubnitz and R. C. Ribeiro (2000). "Clinical importance of minimal 
residual disease in childhood acute lymphoblastic leukemia." Blood 96(8): 2691-2696. 
Daar, A. S. and P. A. Singer (2005). "Pharmacogenetics and geographical ancestry: implications for 
drug development and global health." Nature Reviews Genetics 6(3): 241-246. 
de Jonge, R., J. H. Hooijberg, B. D. van Zelst, G. Jansen, C. H. van Zantwijk, G. J. L. Kaspers, F. G. 
Peters, Y. Ravindranath, R. Pieters and J. Lindemans (2005). "Effect of polymorphisms in folate-
82 
 
related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia." Blood 
106(2): 717-720. 
Dewit, O., T. Moreels, F. Baert, H. Peeters, C. Reenaers, M. De Vos, P. Van Hootegem, V. Muls, G. 
Veereman and F. Mana (2011). "Limitations of extensive TPMT genotyping in the management of 
azathioprine-induced myelosuppression in IBD patients." Clinical biochemistry 44(13): 1062-1066. 
Eichelbaum, M., M. Ingelman-Sundberg and W. E. Evans (2006). "Pharmacogenomics and 
individualized drug therapy." Annu. Rev. Med. 57: 119-137. 
Engen, R., S. Marsh, D. Van Booven and H. McLeod (2006). "Ethnic differences in 
pharmacogenetically relevant genes." Current drug targets 7(12): 1641-1648. 
Evans, W. E., M. Horner, Y. Q. Chu, D. Kalwinsky and W. M. Roberts (1991). "Altered 
mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-
deficient child with acute lymphocytic leukemia." The Journal of pediatrics 119(6): 985-989. 
Evans, W. E. and M. V. Relling (1999). "Pharmacogenomics: translating functional genomics into 
rational therapeutics." science 286(5439): 487-491. 
Evans, W. E. and M. V. Relling (2004). "Moving towards individualized medicine with 
pharmacogenomics." Nature 429(6990): 464-468. 
Evans, W. E., M. V. Relling, J. H. Rodman, W. R. Crom, J. M. Boyett and C.-H. Pui (1998). 
"Conventional compared with individualized chemotherapy for childhood acute lymphoblastic 
leukemia." New England Journal of Medicine 338(8): 499-505. 
Fairchild, C. R., J. Maybaum and K. A. Kennedy (1986). "Concurrent unilateral chromatid damage 
and DNA strand breakage in response to 6-thioguanine treatment." Biochemical pharmacology 
35(20): 3533-3541. 
Farfan, M. J., C. Salas, C. Canales, F. Silva, M. Villarroel, K. Kopp, J. P. Torres, M. E. Santolaya and 
J. Morales (2014). "Prevalence of TPMT and ITPA gene polymorphisms and effect on 
mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia." BMC cancer 14(1): 
299. 
GALIVAN, J. (1980). "Evidence for the cytotoxic activity of polyglutamate derivatives of 
methotrexate." Molecular pharmacology 17(1): 105-110. 
Gao, Y.-J., F.-J. Lu and H.-S. Wang (2006). "Treating childhood acute lymphoblastic leukemia in a 
developing country 1998-2003: the experience of a single children's hospital in China." Journal of 
pediatric hematology/oncology 28(12): 798-802. 
Giovannetti, E., D. G. Ugrasena, E. Supriyadi, L. Vroling, A. Azzarello, D. de Lange, G. J. Peters, A. 
J. Veerman and J. Cloos (2008). "Methylenetetrahydrofolate reductase (MTHFR) C677T and 
thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without 
leukemia." Leukemia research 32(1): 19-24. 
Goggins, W. B. and F. F. Lo (2012). "Racial and ethnic disparities in survival of US children with 
acute lymphoblastic leukemia: evidence from the SEER database 1988–2008." Cancer Causes & 
Control 23(5): 737-743. 
83 
 
Goggins, W. B. and G. Wong (2009). "Cancer among Asian Indians/Pakistanis living in the United 
States: low incidence and generally above average survival." Cancer Causes & Control 20(5): 635-
643. 
Goldstein, D. B., S. K. Tate and S. M. Sisodiya (2003). "Pharmacogenetics goes genomic." Nature 
Reviews Genetics 4(12): 937-947. 
Gonzalez, F. J., R. C. Skodat, S. Kimura, M. Umeno, U. M. Zanger, D. W. Nebert, H. V. Gelboin, J. 
P. Hardwick and U. A. Meyer (1988). "Characterization of the common genetic defect in humans 
deficient in debrisoquine metabolism." 
Greaves, M. (2006). "Infection, immune responses and the aetiology of childhood leukaemia." Nature 
Reviews Cancer 6(3): 193-203. 
Greaves, M. F. and J. Wiemels (2003). "Origins of chromosome translocations in childhood 
leukaemia." Nature Reviews Cancer 3(9): 639-649. 
Gustafsson, G., K. Schmiegelow, E. Forestier, N. Clausen, A. Glomstein, G. Jonmundsson, L. 
Mellander, A. Makipernaa, R. Nygaard and U. Saarinen-Pihkala (2000). "Improving outcome through 
two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the 
reduction of CNS irradiation." Leukemia 14(12): 2267-2275. 
Haferlach, T. (2003). "Thymidylate synthase gene polymorphism and its association with relapse in 
childhood B-cell precursor acute lymphoblastic leukemia." haematologica 88(03): 352-354. 
Hayashi, H., C. Fujimaki, K. Inoue, T. Suzuki and K. Itoh (2007). "Genetic Polymorphism of C452T 
(T127I) in Human. GAMMA.-Glutamyl Hydrolase in a Japanese Population." Biological and 
Pharmaceutical Bulletin 30(4): 839-841. 
Hoang, P. T. V., J. Ambroise, V. L. D. Chi, A.-F. Dekairelle, S. Dupont, N. Huynh, T. B. Nguyen, A. 
Robert, J.-L. Gala and C. Vermylen (2014). "Comparison of Long-term Outcome Between White and 
Vietnamese Children Treated for Acute Lymphoblastic Leukemia According to the FRALLE 2000 
Protocol." Journal of pediatric hematology/oncology 36(7): 534-540. 
Hoffbrand, A. V. and A. B. Mehta (2005). Haematology at a Glance, Blackwell Pub. 
Hon, Y. Y., M. Y. Fessing, C.-H. Pui, M. V. Relling, E. Y. Krynetski and W. E. Evans (1999). 
"Polymorphism of the thiopurine S-methyltransferase gene in African-Americans." Human molecular 
genetics 8(2): 371-376. 
Hooijberg, J. H., H. J. Broxterman, M. Kool, Y. G. Assaraf, G. J. Peters, P. Noordhuis, R. J. Scheper, 
P. Borst, H. M. Pinedo and G. Jansen (1999). "Antifolate resistance mediated by the multidrug 
resistance proteins MRP1 and MRP2." Cancer Research 59(11): 2532-2535. 
Horie, N., H. Aiba, K. Oguro, H. Hojo and K. Takeishi (1995). "Functional analysis and DNA 
polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human 
gene for thymidylate synthase." Cell structure and function 20(3): 191-197. 
Hou, X., S. Wang, Y. Zhou, Z. Xu, Y. Zou, X. Zhu, M. Han, T. Pang and Z. C. Han (2005). "Cyclin 
D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese 
population." International journal of hematology 82(3): 206-209. 
84 
 
Howard, S. C., M. Pedrosa, M. Lins, A. Pedrosa, C.-H. Pui, R. C. Ribeiro and F. Pedrosa (2004). 
"Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic 
leukemia in a resource-poor area." Jama 291(20): 2471-2475. 
Jones, C. D., C. Smart, A. Titus, G. Blyden, M. Dorvil and N. Nwadike (1993). "Thiopurine 
methyltransferase activity in a sample population of black subjects in Florida." Clinical Pharmacology 
& Therapeutics 53(3): 348-353. 
Kager, L. and W. E. Evans (2006). "Pharmacogenomics of acute lymphoblastic leukemia." Current 
opinion in hematology 13(4): 260-265. 
Kim, H., H. J. Kang, H. J. Kim, M. K. Jang, N. H. Kim, Y. Oh, B.-D. Han, J.-Y. Choi, C. W. Kim and 
J. W. Lee (2012). "Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: 
a possible association between survival rate and ITPA polymorphism." PloS one 7(9): e45558. 
Klemetsdal, B., E. Tollefsen, T. Loennechen, K. Johnsen, E. Utsi, K. Gisholt, E. Wist and J. Aarbakke 
(1992). "Interethnic difference in thiopurine methyltransferase activity." Clinical Pharmacology & 
Therapeutics 51(1): 24-31. 
Knudsen, K., J. A. Diehl, C. Haiman and E. Knudsen (2006). "Cyclin D1: polymorphism, aberrant 
splicing and cancer risk." Oncogene 25(11): 1620-1628. 
Koizumi, S., G. A. Curt, R. L. Fine, J. D. Griffin and B. A. Chabner (1985). "Formation of 
methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow." 
Journal of Clinical Investigation 75(3): 1008. 
Koren, G., G. Ferrazini, H. Sulh, A. M. Langevin, J. Kapelushnik, J. Klein, E. Giesbrecht, S. Soldin 
and M. Greenberg (1990). "Systemic exposure to mercaptopurine as a prognostic factor in acute 
lymphocytic leukemia in children." New England Journal of Medicine 323(1): 17-21. 
Krajinovic, M., I. Costea and S. Chiasson (2002). "Polymorphism of the thymidylate synthase gene 
and outcome of acute lymphoblastic leukaemia." The Lancet 359(9311): 1033-1034. 
Krajinovic, M., E. Lemieux-Blanchard, S. Chiasson, M. Primeau, I. Costea and A. Moghrabi (2004). 
"Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute 
lymphoblastic leukemia." The pharmacogenomics journal 4(1): 66-72. 
Kroll, M., C. Stiller, S. Richards, C. Mitchell and L. Carpenter (2012). "Evidence for under-diagnosis 
of childhood acute lymphoblastic leukaemia in poorer communities within Great Britain." British 
journal of cancer 106(9): 1556-1559. 
Krynetski, E. Y., J. D. Schuetz, A. J. Galpin, C.-H. Pui, M. V. Relling and W. E. Evans (1995). "A 
single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase." 
Proceedings of the National Academy of Sciences 92(4): 949-953. 
Krynetski, E. Y., H.-L. Tai, C. R. Yates, M. Y. Fessing, T. Loennechen, J. D. Schuetz, M. V. Relling 
and W. E. Evans (1996). "Genetic polymorphism of thiopurine S-methyltransferase: clinical 
importance and molecular mechanisms." Pharmacogenetics and Genomics 6(4): 279-290. 
Kudo, M., Y. Saito, T. Sasaki, H. Akasaki, Y. Yamaguchi, M. Uehara, K. Fujikawa, M. Ishikawa, N. 
Hirasawa and M. Hiratsuka (2008). "Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, 
and GMPS genes in Japanese individuals." Drug metabolism and pharmacokinetics 24(6): 557-564. 
85 
 
Lee, E. J. and W. Kalow (1993). "Thiopurine S‐methyltransferase activity in a Chinese population." 
Clinical Pharmacology & Therapeutics 54(1): 28-33. 
Lennard, L., B. Gibson, T. Nicole and J. Lilleyman (1993). "Congenital thiopurine methyltransferase 
deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia." 
Archives of disease in childhood 69(5): 577-579. 
Lennard, L., J. Lilleyman, J. Van Loon and R. Weinshilboum (1990). "Genetic variation in response 
to 6-mercaptopurine for childhood acute lymphoblastic leukaemia." The Lancet 336(8709): 225-229. 
Lightfoot, T., W. Johnston, J. Simpson, A. Smith, P. Ansell, S. Crouch, E. Roman and S. Kinsey 
(2012). "Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in 
the United Kingdom." European journal of cancer 48(2): 263-269. 
Lilleyman, J. and L. Lennard (1994). "Mercaptopurine metabolism and risk of relapse in childhood 
lymphoblastic leukaemia." The Lancet 343(8907): 1188-1190. 
Lu, Y., S. K. Y. Kham, A. Hany, A. M. Tan, T. C. Quah and A. E. J. Yeoh (2011). Host 
Pharmacogenetic Factors Significantly Contribute to Refinement of Prognosis in Children with Acute 
Lymphoblastic Leukemia (ALL): Result From the Malaysia-Singapore (Ma-Spore) ALL 2003 Study. 
BLOOD, AMER SOC HEMATOLOGY 1900 M STREET. NW SUITE 200, WASHINGTON, DC 
20036 USA. 
Marinaki, A. M., A. Ansari, J. A. Duley, M. Arenas, S. Sumi, C. M. Lewis, E.-M. Shobowale-Bakre, 
E. Escuredo, L. D. Fairbanks and J. D. Sanderson (2004). "Adverse drug reactions to azathioprine 
therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase 
(ITPase)." Pharmacogenetics and Genomics 14(3): 181-187. 
Marsh, S. (2005). "Thymidylate synthase pharmacogenetics." Investigational new drugs 23(6): 533-
537. 
Marsh, S., M. M. Ameyaw, J. Githang'a, A. Indalo, D. Ofori‐Adjei and H. L. McLeod (2000). "Novel 
thymidylate synthase enhancer region alleles in African populations." Human mutation 16(6): 528-
528. 
Marsh, S. and H. L. McLeod (2006). "Pharmacogenomics: from bedside to clinical practice." Human 
molecular genetics 15(suppl 1): R89-R93. 
Marsh, S. and D. Van Booven (2009). "The increasing complexity of mercaptopurine 
pharmacogenomics." Clinical Pharmacology & Therapeutics 85(2): 139-141. 
Masson, E., M. V. Relling, T. W. Synold, Q. Liu, J. D. Schuetz, J. T. Sandlund, C.-H. Pui and W. E. 
Evans (1996). "Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of 
antileukemic effects in vivo. A rationale for high-dose methotrexate." Journal of Clinical Investigation 
97(1): 73. 
McGuire, J. J., P. Hsieh, J. Coward and J. Bertino (1980). "Enzymatic synthesis of 
folylpolyglutamates. Characterization of the reaction and its products." Journal of Biological 
Chemistry 255(12): 5776-5788. 
McLeod, H., D. Miller and W. Evans (1993). "Azathioprine-induced myelosuppression in thiopurine 
methyltransferase deficient heart transplant recipient." The Lancet 341(8853): 1151. 
86 
 
McLeod, H. L., E. Y. Krynetski, J. A. Wilimas and W. E. Evans (1995). "Higher activity of 
polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults." 
Pharmacogenetics and Genomics 5(5): 281-286. 
McLeod, H. L., J. S. Lin, E. P. Scott, C. H. Pui and W. E. Evans (1994). "Thiopurine 
methyltransferase activity in American white subjects and black subjects." Clinical Pharmacology & 
Therapeutics 55(1): 15-20. 
McLeod, H. L., S. C. Pritchard, J. Githang, A. Indalo, M.-M. Ameyaw, R. H. Powrie, L. Booth and E. 
S. Collie-Duguid (1999). "Ethnic differences in thiopurine methyltransferase pharmacogenetics: 
evidence for allele specificity in Caucasian and Kenyan individuals." Pharmacogenetics and Genomics 
9(6): 773-776. 
Metzger, M. L., S. C. Howard, L. C. Fu, A. Peña, R. Stefan, M. L. Hancock, Z. Zhang, C.-H. Pui, J. 
Wilimas and R. C. Ribeiro (2003). "Outcome of childhood acute lymphoblastic leukaemia in resource-
poor countries." The Lancet 362(9385): 706-708. 
Miller, D. R. (2006). "A tribute to Sidney Farber–the father of modern chemotherapy." British journal 
of haematology 134(1): 20-26. 
Mostert, S., M. N. Sitaresmi, C. M. Gundy and A. J. Veerman (2006). "Influence of socioeconomic 
status on childhood acute lymphoblastic leukemia treatment in Indonesia." Pediatrics 118(6): e1600-
e1606. 
Motulsky, A. G. (1957). "Drug reactions, enzymes, and biochemical genetics." Journal of the 
American Medical Association 165(7): 835-837. 
Nebert, D. W., G. Zhang and E. S. Vesell (2008). "From human genetics and genomics to 
pharmacogenetics and pharmacogenomics: past lessons, future directions." Drug metabolism reviews 
40(2): 187-224. 
Need, A. C., A. G. Motulsky and D. B. Goldstein (2005). "Priorities and standards in pharmacogenetic 
research." Nature genetics 37(7): 671-681. 
Nguyen, K., M. Devidas, S.-C. Cheng, M. La, E. A. Raetz, W. L. Carroll, N. J. Winick, S. P. Hunger, 
P. S. Gaynon and M. L. Loh (2008). "Factors influencing survival after relapse from acute 
lymphoblastic leukemia: a Children's Oncology Group study." Leukemia 22(12): 2142-2150. 
Nygaard, U. and K. Schmiegelow (2003). "Dose reduction of coadministered 6-mercaptopurine 
decreases myelotoxicity following high-dose methotrexate in childhood leukemia." Leukemia 17(7): 
1344-1348. 
Olsen, M., H. O. Madsen, H. Hjalgrim, J. Gregers, K. Rostgaard and K. Schmiegelow (2006). 
"Preleukemic TEL-AML1–positive Clones at Cell Level of 10− 3 to 10− 4 do not Persist into 
Adulthood." Journal of pediatric hematology/oncology 28(11): 734-740. 
Onay, U. V., K. Aaltonen, L. Briollais, J. A. Knight, N. Pabalan, O. Kilpivaara, I. L. Andrulis, C. 
Blomqvist, H. Nevanlinna and H. Ozcelik (2008). "Combined effect of CCND1 and COMT 
polymorphisms and increased breast cancer risk." BMC cancer 8(1): 6. 
Organista-Nava, J., Y. Gómez-Gómez, M. V. Saavedra-Herrera, A. B. Rivera-Ramírez, M. A. Terán-
Porcayo, L. del Carmen Alarcón-Romero, B. Illades-Aguiar and M. A. Leyva-Vázquez (2010). 
87 
 
"Polymorphisms of the γ-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia 
in Mexico." Leukemia research 34(6): 728-732. 
Otterness, D., C. Szumlanski, L. Lennard, B. Klemetsdal, J. Aarbakke, J. O. Park‐Hah, H. Iven, K. 
Schmiegelow, E. Branum and J. O'Brien (1997). "Human thiopurine methyltransferase 
pharmacogenetics: gene sequence polymorphisms." Clinical Pharmacology & Therapeutics 62(1): 60-
73. 
Pabalan, N., B. Bapat, L. Sung, H. Jarjanazi, O. Francisco-Pabalan and H. Ozcelik (2008). "Cyclin D1 
Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human 
populations: a meta-analysis." Cancer Epidemiology Biomarkers & Prevention 17(10): 2773-2781. 
Panetta, J. C., A. Wall, C.-H. Pui, M. V. Relling and W. E. Evans (2002). "Methotrexate Intracellular 
Disposition in Acute Lymphoblastic Leukemia A Mathematical Model of γ-Glutamyl Hydrolase 
Activity." Clinical cancer research 8(7): 2423-2429. 
Patil, N., A. J. Berno, D. A. Hinds, W. A. Barrett, J. M. Doshi, C. R. Hacker, C. R. Kautzer, D. H. 
Lee, C. Marjoribanks and D. P. McDonough (2001). "Blocks of limited haplotype diversity revealed 
by high-resolution scanning of human chromosome 21." Science 294(5547): 1719-1723. 
Phaichitchinda, P. (2005). Cyclin D1 Genetic Polymorphism and Clinical Presentation of Childhood 
Acute Lymphoblastic Leukemia, Mahidol University. 
Pirmohamed, M. (2001). "Pharmacogenetics and pharmacogenomics." British journal of clinical 
pharmacology 52(4): 345-347. 
Pizzo, P. A., D. G. Poplack, P. C. Adamson, S. M. Blaney and L. J. Helman (2006). Principles and 
practice of pediatric oncology, Lippincott Williams & Wilkins Philadelphia, PA:. 
Przekop, P. R., H. Tulgan, A. A. Przekop and M. Glantz (2006). "Adverse drug reaction to 
methotrexate: pharmacogenetic origin." JAOA: Journal of the American Osteopathic Association 
106(12): 706-707. 
Pui, C.-H. and W. E. Evans (2006). "Treatment of acute lymphoblastic leukemia." New England 
Journal of Medicine 354(2): 166-178. 
Pui, C.-H., L. L. Robison and A. T. Look (2008). "Acute lymphoblastic leukaemia." The Lancet 
371(9617): 1030-1043. 
Quoc, N. M., N. C. Hung, E. Kramarova and D. Parkin (2000). "Incidence of childhood cancer in Ho 
Chi Minh City, Vietnam, 1995–97." Paediatric and perinatal epidemiology 14(3): 240-247. 
Radparvar, S., P. J. Houghton and J. A. Houghton (1988). "Characteristics of thymidylate synthase 
purified from a human colon adenocarcinoma." Archives of biochemistry and biophysics 260(1): 342-
350. 
Reaman, G. H. (2002). "Pediatric oncology: current views and outcomes." Pediatric Clinics of North 
America 49(6): 1305-1318. 
Rech, A., G. P. de Carvalho, C. F. Meneses, J. Hankins, S. Howard and A. L. Brunetto (2005). "The 
influence of traumatic lumbar puncture and timing of intrathecal therapy on outcome of pediatric 
acute lymphoblastic leukemia." Pediatric Hematology-Oncology 22(6): 483-488. 
88 
 
Redaniel, M., A. Laudico, M. Mirasol-Lumague, A. Alcasabas, D. Pulte and H. Brenner (2010). 
"Geographic and ethnic differences in childhood leukaemia and lymphoma survival: comparisons of 
Philippine residents, Asian Americans and Caucasians in the United States." British journal of cancer 
103(1): 149-154. 
Relling, M. V., M. L. Hancock, J. M. Boyett, C.-H. Pui and W. E. Evans (1999). "Prognostic 
importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia." Blood 93(9): 2817-
2823. 
Relling, M. V., M. L. Hancock, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, E. Y. Krynetski, C.-H. 
Pui and W. E. Evans (1999). "Mercaptopurine therapy intolerance and heterozygosity at the thiopurine 
S-methyltransferase gene locus." Journal of the National Cancer Institute 91(23): 2001-2008. 
Ren, S. and B. J. Rollins (2004). "Cyclin C/cdk3 promotes Rb-dependent G0 exit." Cell 117(2): 239-
251. 
Rhee, M., B. Lindau-Shepard, K. Chave, J. Galivan and T. Ryan (1998). "Characterization of human 
cellular γ-glutamyl hydrolase." Molecular pharmacology 53(6): 1040-1046. 
Ribeiro, R. C. and C.-H. Pui (2005). "Saving the children—improving childhood cancer treatment in 
developing countries." New England Journal of Medicine 352(21): 2158-2160. 
Robien, K., M. Schubert, T. Chay, J. Bigler, R. Storb, Y. Yasui, J. Potter and C. Ulrich (2006). 
"Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis 
severity following hematopoietic stem cell transplantation." Bone marrow transplantation 37(8): 799-
800. 
Rocha, J. C. C., C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro 
and D. Campana (2005). "Pharmacogenetics of outcome in children with acute lymphoblastic 
leukemia." Blood 105(12): 4752-4758. 
Roses, A. D. (2000). "Pharmacogenetics and the practice of medicine." Nature 405(6788): 857-865. 
Rots, M. G., R. Pieters, G. J. Peters, P. Noordhuis, C. H. Van Zantwijk, G. Henze, G. E. Janka‐
Schaub, A. J. Veerman and G. Jansen (2000). "Methotrexate resistance in relapsed childhood acute 
lymphoblastic leukaemia." British journal of haematology 109(3): 629-634. 
Sasaki, T., E. Goto, Y. Konno, M. Hiratsuka and M. Mizugaki (2006). "Three novel single nucleotide 
polymorphisms of the human thiopurine S-methyltransferase gene in Japanese individuals." Drug 
metabolism and pharmacokinetics 21(4): 332-336. 
Schmiegelow, K. and U. Bretton-Meyer (2001). "6-mercaptopurine dosage and pharmacokinetics 
influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute 
lymphoblastic leukemia." Leukemia 15(1): 74-79. 
Schmiegelow, K., C. Nyvold, J. Seyfarth, R. Pieters, M. Rottier, N. Knabe, L. Ryder, H. Madsen, A. 
Svejgaard and G. Kaspers (2001). "Post-induction residual leukemia in childhood acute lymphoblastic 
leukemia quantified by PCR correlates with in vitro prednisolone resistance." Leukemia 15(7): 1066-
1071. 
Schmiegelow, K., H. Schrøder, G. Gustafsson, J. Kristinsson, A. Glomstein, T. Salmi and L. Wranne 
(1995). "Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate 
89 
 
and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric 
Hematology and Oncology." Journal of Clinical Oncology 13(2): 345-351. 
Schmiegelow, K., H. Schrøder and M. Schmiegelow (1994). "Methotrexate and 6-mercaptopurine 
maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell 
counts or by pharmacokinetic parameters?" Cancer chemotherapy and pharmacology 34(3): 209-215. 
Schornagel, J. and J. McVie (1983). "The clinical pharmacology of methotrexate." Cancer treatment 
reviews 10(1): 53-75. 
Schrappe, M., B. Camitta, C. Pui, T. Eden, P. Gaynon, G. Gustafsson, G. Janka-Schaub, W. Kamps, 
G. Masera and S. Sallan (2000). "Long-term results of large prospective trials in childhood acute 
lymphoblastic leukemia." Leukemia 14(12): 2193. 
Schrappe, M., A. Reiter, W.-D. Ludwig, J. Harbott, M. Zimmermann, W. Hiddemann, C. Niemeyer, 
G. Henze, A. Feldges and F. Zintl (2000). "Improved outcome in childhood acute lymphoblastic 
leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 
90." Blood 95(11): 3310-3322. 
Schwab, M. and U. Klotz (2001). "Pharmacokinetic considerations in the treatment of inflammatory 
bowel disease." Clinical pharmacokinetics 40(10): 723-751. 
Sheaff, R. J., M. Groudine, M. Gordon, J. M. Roberts and B. E. Clurman (1997). "Cyclin E-CDK2 is a 
regulator of p27Kip1." Genes & development 11(11): 1464-1478. 
Sherr, C. J. (1996). "Cancer cell cycles." Science 274(5293): 1672-1677. 
Sherr, C. J. and J. M. Roberts (1999). "CDK inhibitors: positive and negative regulators of G1-phase 
progression." Genes & development 13(12): 1501-1512. 
Shu, X. O., D. B. Moore, Q. Cai, J. Cheng, W. Wen, L. Pierce, H. Cai, Y.-T. Gao and W. Zheng 
(2005). "Association of cyclin D1 genotype with breast cancer risk and survival." Cancer 
Epidemiology Biomarkers & Prevention 14(1): 91-97. 
Sirachainan, N., S. Wongruangsri, S. Kajanachumpol, S. Pakakasama, A. Visudtibhan, I. 
Nuchprayoon, A. Lusawat, S. Phudhicharoenrat, S. Shuangshoti and S. Hongeng (2008). "Folate 
pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children." 
Cancer detection and prevention 32(1): 72-78. 
Sobti, R., P. Kaur, S. Kaur, J. Singh, A. Janmeja, S. Jindal, J. Kishan and S. Raimondi (2006). "Effects 
of cyclin D1 (CCND1) polymorphism on susceptibility to lung cancer in a North Indian population." 
Cancer genetics and cytogenetics 170(2): 108-114. 
Spire‐Vayron de la Moureyre, C., H. Debuysere, B. Mastain, E. Vinner, D. Marez, J. M. Lo Guidice, 
D. Chevalier, S. Brique, K. Motte and J. F. Colombel (1998). "Genotypic and phenotypic analysis of 
the polymorphic thiopurine S‐methyltransferase gene (TPMT) in a European population." British 
journal of pharmacology 125(4): 879-887. 
Stanulla, M., E. Schaeffeler, T. Flohr, G. Cario, A. Schrauder, M. Zimmermann, K. Welte, W.-D. 
Ludwig, C. R. Bartram and U. M. Zanger (2005). "Thiopurine methyltransferase (TPMT) genotype 
and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia." Jama 
293(12): 1485-1489. 
90 
 
Stiller, C. A. (2004). "Epidemiology and genetics of childhood cancer." Oncogene 23(38): 6429-6444. 
Stocco, G., M. Cheok, K. Crews, T. Dervieux, D. French, D. Pei, W. Yang, C. Cheng, C. Pui and M. 
Relling (2009). "Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of 
mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia." Clinical 
Pharmacology & Therapeutics 85(2): 164-172. 
Stocco, G., K. R. Crews and W. E. Evans (2010). "Genetic polymorphism of inosine-triphosphate-
pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute 
lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status." Expert opinion on 
drug safety 9(1): 23-37. 
Sumi, S., A. M. Marinaki, M. Arenas, L. Fairbanks, M. Shobowale-Bakre, D. C. Rees, S. Thein, A. 
Ansari, J. Sanderson and R. A. De Abreu (2002). "Genetic basis of inosine triphosphate 
pyrophosphohydrolase deficiency." Human genetics 111(4-5): 360-367. 
Synold, T. W., M. V. Relling, J. M. Boyett, G. K. Rivera, J. T. Sandlund, H. Mahmoud, W. Crist, C. 
Pui and W. Evans (1994). "Blast cell methotrexate-polyglutamate accumulation in vivo differs by 
lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia." Journal of Clinical 
Investigation 94(5): 1996. 
SZUMLANSKI, C., D. OTTERNESS, C. HER, D. LEE, B. BRANDRIFF, D. KELSELL, N. SPURR, 
L. LENNARD, E. WIEBEN and R. WEINSHILBOUM (1996). "Thiopurine methyltransferase 
pharmacogenetics: human gene cloning and characterization of a common polymorphism." DNA and 
cell biology 15(1): 17-30. 
Tai, H.-L., E. Y. Krynetski, E. G. Schuetz, Y. Yanishevski and W. E. Evans (1997). "Enhanced 
proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT∗ 
3A, TPMT∗ 2): mechanisms for the genetic polymorphism of TPMT activity." Proceedings of the 
National Academy of Sciences 94(12): 6444-6449. 
Tang, W. K. B. and L. Endrenyi (1998). "Hypothesis: comparisons of inter-and intra-individual 
variations can substitute for twin studies in drug research." Pharmacogenetics and Genomics 8(4): 
283-289. 
Tang, Y., X. Xu, H. Song, S. Yang, S. Shi and J. Wei (2008). "Long‐term outcome of childhood acute 
lymphoblastic leukemia treated in China." Pediatric blood & cancer 51(3): 380-386. 
Tate, S. K. and D. B. Goldstein (2004). "Will tomorrow's medicines work for everyone?" Nature 
genetics 36: S34-S42. 
They-They, T. P., K. Hamzi, A. Mazabraud and S. Nadifi (2009). "Frequency of C677T 
polymorphism of methylene tetrahyrofolate reductase (MTHFR) gene among berber and arabic 
Moroccan populations." Antropo 20: 11-17. 
Thyss, A., J. Kubar, G. Milano, M. Namer and M. Schneider (1986). "Clinical and pharmacokinetic 
evidence of a life-threatening interaction between methotrexate and ketoprofen." The Lancet 
327(8475): 256-258. 
Tiseo, M., E. Giovannetti, C. Tibaldi, A. Camerini, F. Di Costanzo, F. Barbieri, J. A. Burgers, A. 
Vincent, G. J. Peters and E. F. Smit (2012). "Pharmacogenetic study of patients with advanced non-
91 
 
small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin." 
Lung Cancer 78(1): 92-99. 
Tishkoff, S. A. and B. C. Verrelli (2003). "Patterns of human genetic diversity: implications for 
human evolutionary history and disease." Annual review of genomics and human genetics 4(1): 293-
340. 
Tumer, T. B., G. Ulusoy, O. Adali, G. Sahin, S. Gozdasoglu and E. Arinç (2007). "The low frequency 
of defective TPMT alleles in Turkish population: a study on pediatric patients with acute 
lymphoblastic leukemia." American journal of hematology 82(10): 906-910. 
Urayama, K. Y., P. A. Buffler, E. R. Gallagher, J. M. Ayoob and X. Ma (2010). "A meta-analysis of 
the association between day-care attendance and childhood acute lymphoblastic leukaemia." 
International journal of epidemiology 39(3): 718-732. 
van Dongen, J. J., T. Seriu, E. R. Panzer-Grümayer, A. Biondi, M. J. Pongers-Willemse, L. Corral, F. 
Stolz, M. Schrappe, G. Masera and W. A. Kamps (1998). "Prognostic value of minimal residual 
disease in acute lymphoblastic leukaemia in childhood." The Lancet 352(9142): 1731-1738. 
Viana, M. B., R. Fernandes, B. M. de Oliveira, M. Murao, C. de Andrade Paes and A. A. Duarte 
(2001). "Nutritional and socio-economic status in the prognosis of childhood acute lymphoblastic 
leukemia." haematologica 86(2): 113-120. 
Vogel, F. (1959). Moderne probleme der humangenetik. Ergebnisse der inneren medizin und 
kinderheilkunde, Springer: 52-125. 
von Stackelberg, A., R. Hartmann, C. Bührer, R. Fengler, G. Janka-Schaub, A. Reiter, G. Mann, K. 
Schmiegelow, R. Ratei and T. Klingebiel (2008). "High-dose compared with intermediate-dose 
methotrexate in children with a first relapse of acute lymphoblastic leukemia." Blood 111(5): 2573-
2580. 
Weinshilboum, R. M. and S. L. Sladek (1980). "Mercaptopurine pharmacogenetics: monogenic 
inheritance of erythrocyte thiopurine methyltransferase activity." American journal of human genetics 
32(5): 651. 
Welsh, S. J., J. Titley, L. Brunton, M. Valenti, P. Monaghan, A. L. Jackman and G. W. Aherne (2000). 
"Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in 
normal and tumor cell lines and tissues." Clinical cancer research 6(6): 2538-2546. 
Whitehead, V., M. Vuchich, S. Lauer, D. Mahoney, A. Carroll, J. Shuster, D. Esseltine, C. Payment, 
A. Look and J. Akabutu (1992). "Accumulation of high levels of methotrexate polyglutamates in 
lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute 
lymphoblastic leukemia: a Pediatric Oncology Group study." Blood 80(5): 1316-1323. 
Whitehead, V. M., D. S. Rosenblatt, M.-J. Vuchich, J. J. Shuster, A. Witte and D. Beaulieu (1990). 
"Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of 
childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis." Blood 76(1): 44-49. 
Wiemels, J. (2012). "Perspectives on the causes of childhood leukemia." Chemico-biological 
interactions 196(3): 59-67. 
92 
 
Wilson, J. F., M. E. Weale, A. C. Smith, F. Gratrix, B. Fletcher, M. G. Thomas, N. Bradman and D. B. 
Goldstein (2001). "Population genetic structure of variable drug response." Nature genetics 29(3): 
265-269. 
Wolf, C. R., G. Smith and R. L. Smith (2000). "Science, medicine, and the future: Pharmacogenetics." 
BMJ: British Medical Journal 320(7240): 987. 
Yang, Y. L., D. T. Lin, S. K. Chang, S. R. Lin, S. W. Lin, R. J. Chiou, C. T. Yen, K. H. Lin, S. T. Jou 
and M. Y. Lu (2010). "Pharmacogenomic variations in treatment protocols for childhood acute 
lymphoblastic leukemia." Pediatric blood & cancer 54(2): 206-211. 
Yasmeen, N. and S. Ashraf (2009). "Childhood acute lymphoblastic leukaemia; epidemiology and 
clinicopathological features." JPMA 59(150). 
Yates, C. R., E. Y. Krynetski, T. Loennechen, M. Y. Fessing, H.-L. Tai, C.-H. Pui, M. V. Relling and 
W. E. Evans (1997). "Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis 
for azathioprine and mercaptopurine intolerance." Annals of internal medicine 126(8): 608-614. 
Zeng, H., Z.-S. Chen, M. G. Belinsky, P. A. Rea and G. D. Kruh (2001). "Transport of Methotrexate 
(MTX) and Folates by Multidrug Resistance Protein (MRP) 3 and MRP1 Effect of Polyglutamylation 
on MTX Transport." Cancer research 61(19): 7225-7232. 
Zhou, S. (2006). "Clinical pharmacogenomics of thiopurine S-methyltransferase." Current clinical 
pharmacology 1(1): 119-128. 
  
93 
 
 
 
 
 
 
 
APPENDIX 
  
94 
 
STUDY I (published) 
 
95 
 
 
  
96 
 
 
  
97 
 
 
  
98 
 
 
  
99 
 
  
100 
 
 
  
101 
 
STUDY II (published) 
 
 
 
102 
 
 
 
 
103 
 
 
 
 
104 
 
 
 
 
105 
 
 
 
 
106 
 
 
 
107 
 
 
 
 
108 
 
 
 
 
109 
 
 
 
 
110 
 
 
 
111 
 
 
 
 
112 
 
 
 
 
